<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31607902</article-id>
<article-id pub-id-type="pmc">6755339</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2019.01022</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>N-3 Polyunsaturated Fatty Acids and the Resolution of Neuroinflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Joffre</surname>
<given-names>Corinne</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/609255" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rey</surname>
<given-names>Charlotte</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Layé</surname>
<given-names>Sophie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/7865" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>INRA, Nutrition et Neurobiologie Intégrée, UMR 1286</institution>, <addr-line>Bordeaux</addr-line>, <country>France</country></aff>
<aff id="aff2"><sup>2</sup><institution>Université de Bordeaux 2</institution>, <addr-line>Bordeaux</addr-line>, <country>France</country></aff>
<aff id="aff3"><sup>3</sup><institution>ITERG, Nutrition Health and Lipid Biochemistry Department</institution>, <addr-line>Canéjan</addr-line>, <country>France</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Pietro Giusti, University of Padova, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Luigia Trabace, University of Foggia, Italy; Antonio Carlos Pinheiro De Oliveira, Federal University of Minas Gerais, Brazil</p>
</fn>
<corresp id="fn001">*Correspondence: Corinne Joffre, <email xlink:href="mailto:corinne.joffre@inra.fr" xlink:type="simple">corinne.joffre@inra.fr</email></corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>9</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>1022</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>8</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Joffre, Rey and Layé</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Joffre, Rey and Layé</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>In the past few decades, as a result of their anti-inflammatory properties, n-3 long chain polyunsaturated fatty acids (n-3 LC-PUFAs), have gained greater importance in the regulation of inflammation, especially in the central nervous system (in this case known as neuroinflammation). If sustained, neuroinflammation is a common denominator of neurological disorders, including Alzheimer’s disease and major depression, and of aging. Hence, limiting neuroinflammation is a real strategy for neuroinflammatory disease therapy and treatment. Recent data show that n-3 LC-PUFAs exert anti-inflammatory properties in part through the synthesis of specialized pro-resolving mediators (SPMs) such as resolvins, maresins and protectins. These SPMs are crucially involved in the resolution of inflammation. They could be good candidates to resolve brain inflammation and to contribute to neuroprotective functions and could lead to novel therapeutics for brain inflammatory diseases. This review presents an overview 1) of brain n-3 LC-PUFAs as precursors of SPMs with an emphasis on the effect of n-3 PUFAs on neuroinflammation, 2) of the formation and action of SPMs in the brain and their biological roles, and the possible regulation of their synthesis by environmental factors such as inflammation and nutrition and, in particular, PUFA consumption.</p>
</abstract>
<kwd-group>
<kwd>n-3 long-chain PUFAs</kwd>
<kwd>docosahexaenoic acid</kwd>
<kwd>eicosapentaenoic acid</kwd>
<kwd>specialized pro-resolving mediators</kwd>
<kwd>nutrition</kwd>
<kwd>neuroinflammation</kwd>
<kwd>resolvins</kwd>
</kwd-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="235"></ref-count>
<page-count count="16"></page-count>
<word-count count="8133"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Inflammation is a critical process in host defense, facilitating tissue repair, regeneration and maintenance of homeostasis. However, if uncontrolled, it becomes a chronic low-grade inflammation that is characterized by the production of pro-inflammatory cytokines and adipokines leading to tissue damage and loss of function (<xref ref-type="bibr" rid="B131">López-Vicario et al., 2016</xref>). This chronic low-grade inflammation is observed in many chronic pathologies including neurodegenerative diseases and also in aging. Hence it becomes a significant public health concern and constitutes a financial burden that impacts millions worldwide (<xref ref-type="bibr" rid="B182">Serhan, 2017b</xref>). It is thus of importance to find treatments that ensure resolution of inflammation in a specific time-limited manner. Nutrition has gained importance in recent years since nutriments such as n-3 polyunsaturated fatty acids (PUFAs) have anti-inflammatory properties (<xref ref-type="bibr" rid="B30">Calder, 2016</xref>; <xref ref-type="bibr" rid="B31">Calder et al., 2017</xref>). They exert their effect in part through their conversion into bioactive lipid mediators called specialized pro-resolving mediators (SPMs) that underlie most of the beneficial effects attributed to their precursors (<xref ref-type="bibr" rid="B180">Serhan, 2014</xref>; <xref ref-type="bibr" rid="B131">López-Vicario et al., 2016</xref>). Recently, attention has been paid to these derivatives in the regulation of neuroinflammation. In this review, we present an overview of brain n-3 PUFAs and their effect on neuroinflammation and of the formation and mechanisms of the action of SPMs in the brain.</p>
</sec>
<sec id="s2">
<title>Brain N-3 PUFAs as Precursors of SPMs</title>
<sec id="s2_1">
<title>Brain n-3 PUFAs</title>
<p>The brain contains high levels of PUFAs (25–30%) that are mainly docosahexaenoic acid (DHA, n-3 PUFA) (12–14% of total fatty acids) and arachidonic acid (AA, n-6 PUFA) (8–10% of total fatty acids) (<xref ref-type="bibr" rid="B32">Carrie et al., 2000</xref>; <xref ref-type="bibr" rid="B228">Xiao et al., 2005</xref>; <xref ref-type="bibr" rid="B143">McNamara and Carlson, 2006</xref>; <xref ref-type="bibr" rid="B129">Little et al., 2007</xref>; <xref ref-type="bibr" rid="B43">Chung et al., 2008</xref>; <xref ref-type="bibr" rid="B103">Joffre et al., 2016</xref>). There are regional differences: the hippocampus and prefrontal cortex contain the highest DHA content whereas the hypothalamus has the lowest (<xref ref-type="bibr" rid="B32">Carrie et al., 2000</xref>; <xref ref-type="bibr" rid="B228">Xiao et al., 2005</xref>; <xref ref-type="bibr" rid="B103">Joffre et al., 2016</xref>). There are also cellular differences: astrocytes, oligodendrocytes, and microglial cells (representing respectively 70%, 10–15% and 10–15% of brain glial cells; <xref ref-type="bibr" rid="B171">Renaud et al., 2015</xref>) contain DHA in different proportions. DHA represents 10–12% in astrocytes, 5% in the oligodendrocytes and up to 2% in microglial cells (<xref ref-type="bibr" rid="B22">Bourre et al., 1984</xref>; <xref ref-type="bibr" rid="B174">Rey et al., 2018</xref>). Neurons cannot synthesize long-chain PUFAs (LC-PUFAs) but can incorporate them in their membranes: DHA represents 8.3% of the total fatty acids in neurons (<xref ref-type="bibr" rid="B22">Bourre et al., 1984</xref>).</p>
<p>Numerous studies have discussed the transport of DHA through the blood–brain barrier (BBB). DHA enters the brain as unesterified DHA that is the major pool supplying the brain with DHA. However, the precise mechanisms of entry are still not fully described. Some transporters facilitate the uptake of DHA into the brain: fatty acid transport proteins (FATPs), fatty acid translocase (CD36) and major facilitator superfamily domain containing 2A (MFSD2A) (<xref ref-type="bibr" rid="B42">Chouinard-Watkins and Bazinet, 2018</xref>). <xref ref-type="bibr" rid="B73">Fernandez et al. (2018)</xref> recently reported that a member of the long-chain acyl-CoA synthetase (ACSL) family, ACSL6, is also involved in brain DHA uptake but its role has yet to be determined (<xref ref-type="bibr" rid="B73">Fernandez et al., 2018</xref>).</p>
<p>This brain fatty acid composition can be affected by environmental factors such as nutrition, something to which individuals are continuously exposed. Indeed, the PUFA content in all brain structures is strongly impacted by the PUFAs present in the diet (<xref ref-type="bibr" rid="B3">Alashmali et al., 2016</xref>; <xref ref-type="bibr" rid="B103">Joffre et al., 2016</xref>). A diet rich in n-3 PUFAs (DHA found in fish or its precursor, alpha-linolenic acid, found in vegetable oil) increases brain DHA in rodents (<xref ref-type="bibr" rid="B94">Hiratsuka et al., 2009</xref>; <xref ref-type="bibr" rid="B56">de Theije et al., 2015</xref>; <xref ref-type="bibr" rid="B198">Skorve et al., 2015</xref>; <xref ref-type="bibr" rid="B109">Kitson et al., 2016</xref>). However, DHA supplementation is more effective than alpha-linolenic supplementation in increasing the DHA content in the brain (<xref ref-type="bibr" rid="B118">Lacombe et al., 2017</xref>; <xref ref-type="bibr" rid="B172">Rey et al., 2019</xref>). In rodents, DHA supplementation from 16 weeks to 16 months or from 20 to 22 months of age compensates a DHA decrease due to aging (<xref ref-type="bibr" rid="B129">Little et al., 2007</xref>; <xref ref-type="bibr" rid="B117">Labrousse et al., 2012</xref>; <xref ref-type="bibr" rid="B13">Bascoul- Colombo et al., 2016</xref>). On the other hand, a diet deficient in n-3 PUFAs decreases brain DHA in all brain structures, with the hippocampus, containing most DHA, being the most affected and the hypothalamus the least affected (<xref ref-type="bibr" rid="B59">Delpech et al., 2015b</xref>; <xref ref-type="bibr" rid="B103">Joffre et al., 2016</xref>; <xref ref-type="bibr" rid="B138">Manduca et al., 2017</xref>).</p>
<p>Studies from Broadhurst and Crawford suggest that the amount of DHA incorporated into the brain depends on the complexity of the brain structure and on behavior development (<xref ref-type="bibr" rid="B48">Crawford et al., 1999</xref>; <xref ref-type="bibr" rid="B25">Broadhurst et al., 2002</xref>). A decrease in brain DHA induced by a deficient diet during gestation and lactation can be reversed by 2-month DHA supplementation at weaning (<xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>). The organism also adapts its metabolism to an n-3 PUFA deficiency condition: the half-life of DHA increases in the brain to reduce its loss (<xref ref-type="bibr" rid="B168">Rapoport et al., 2007</xref>) and the activity of the enzymes responsible for DHA conversion, the ∆6 desaturase and elongase, is increased in the liver (<xref ref-type="bibr" rid="B41">Cho et al., 1999</xref>; <xref ref-type="bibr" rid="B221">Wang et al., 2005</xref>; <xref ref-type="bibr" rid="B98">Igarashi et al., 2007</xref>). Brain cells are also impacted by dietary PUFA supply. An n-3 PUFA deficient diet decreases DHA in astrocytes, neurons and oligodendrocytes (<xref ref-type="bibr" rid="B22">Bourre et al., 1984</xref>) whereas n-3 PUFA supplementation increases DHA levels in glial cells (<xref ref-type="bibr" rid="B24">Bowen and Clandinin, 2005</xref>; <xref ref-type="bibr" rid="B60">Destaillats et al., 2010</xref>). Moreover, we recently showed that the fatty acid composition of the microglial cells is also modulated by n-3 PUFA dietary intake during the gestation/lactation period. Maternal n-3 LC-PUFA dietary supplementation during gestation and lactation increases the DHA level in the offspring’s microglia at P21 as compared with a maternal diet that contains equilibrated levels of n-6 and n-3 PUFA precursors (<xref ref-type="bibr" rid="B174">Rey et al., 2018</xref>). Interestingly, maternal n-3 PUFA deficiency does not impact the DHA level suggesting that microglial cells are protected from n-3 PUFA deficiency (<xref ref-type="bibr" rid="B174">Rey et al., 2018</xref>).</p>
</sec>
<sec id="s2_2">
<title>n-3 PUFAs as Regulators of Neuroinflammation</title>
<p>n-3 PUFAs have powerful anti-inflammatory properties (<xref ref-type="bibr" rid="B29">Calder, 2005</xref>). They play an important role in the regulation of the synthesis and release of pro-inflammatory mediators (<xref ref-type="bibr" rid="B59">Delpech et al., 2015b</xref>; <xref ref-type="bibr" rid="B89">Hanisch and Kettenmann, 2007</xref>; <xref ref-type="bibr" rid="B49">Cunningham and Sanderson, 2008</xref>; <xref ref-type="bibr" rid="B233">Yirmiya and Goshen, 2011</xref>; <xref ref-type="bibr" rid="B160">Pascual et al., 2012</xref>). Pro-inflammatory factors include interleukin-1 beta (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) and play a role in neuronal plasticity (<xref ref-type="bibr" rid="B59">Delpech et al., 2015b</xref>; <xref ref-type="bibr" rid="B233">Yirmiya and Goshen, 2011</xref>). If sustained, uncontrolled inflammation can lead to neuronal damage that is involved in many neuronal pathologies (<xref ref-type="bibr" rid="B20">Blais and Rivest, 2003</xref>; <xref ref-type="bibr" rid="B123">Layé, 2010</xref>; <xref ref-type="bibr" rid="B199">Solito and Sastre, 2012</xref>). Hence, limiting the inflammation and enhancing the resolution of inflammation is of great interest.</p>
<sec id="s2_2_1">
<title>Evidence in Humans</title>
<p>In humans, the anti-inflammatory properties of n-3 PUFAs were first identified in epidemiological studies in Eskimos that consume a lot of n-3 LC-PUFAs from eating fish (<xref ref-type="bibr" rid="B68">Dyerberg and Bang, 1979</xref>; <xref ref-type="bibr" rid="B115">Kromann and Green, 1980</xref>; <xref ref-type="bibr" rid="B196">Simopoulos, 2008</xref>). Clinical studies have highlighted the beneficial effect of n-3 LC-PUFAs in chronic inflammatory and autoimmune diseases. Indeed, fish oil supplementation decreases pro-inflammatory cytokine expression, such as IL-1β in blood monocytes, and improves the symptoms of patients suffering from rheumatoid arthritis (<xref ref-type="bibr" rid="B112">Kremer et al., 1990</xref>; <xref ref-type="bibr" rid="B102">James et al., 1997</xref>; <xref ref-type="bibr" rid="B111">Kremer, 2000</xref>) or multiple sclerosis (<xref ref-type="bibr" rid="B205">Stewart and Bowling, 2005</xref>; <xref ref-type="bibr" rid="B223">Weinstock-Guttman et al., 2005</xref>). Moreover, DHA supply significantly decreases the circulating inflammatory markers and the oxidative stress (<xref ref-type="bibr" rid="B79">Freund-Levi et al., 2006</xref>; <xref ref-type="bibr" rid="B107">Kiecolt-Glaser et al., 2012</xref>). DHA supply for several months also improves the working and long-term memories in patients with moderate cognitive alterations (<xref ref-type="bibr" rid="B79">Freund-Levi et al., 2006</xref>; <xref ref-type="bibr" rid="B126">Lee et al., 2013</xref>).</p>
</sec>
<sec id="s2_2_2">
<title>Evidence in Animals</title>
<p>In animals, numerous studies have demonstrated the anti-inflammatory properties of n-3 PUFAs in the brain. In lipopolysaccharide (LPS)-, or IL-1β-, induced inflammation models, dietary n-3 LC-PUFA supplementation in adulthood prevents LPS-induced hippocampal increase of pro-inflammatory cytokines IL-1β and TNF-α in rats and mice (<xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>; <xref ref-type="bibr" rid="B57">Dehkordi et al., 2015</xref>; <xref ref-type="bibr" rid="B172">Rey et al., 2019</xref>). A dietary supply in eicosapentaenoic acid (EPA) decreases the production of LPS-induced pro-inflammatory cytokines IL-1β, IL-6 and TNF-α in the hippocampus and increases the production of anti-inflammatory cytokines IL-10 and IL-4 in both rats (<xref ref-type="bibr" rid="B106">Kavanagh et al., 2004</xref>; <xref ref-type="bibr" rid="B130">Lonergan et al., 2004</xref>; <xref ref-type="bibr" rid="B66">Dong et al., 2017</xref>) and mice (<xref ref-type="bibr" rid="B194">Shi et al., 2016</xref>). This modification is associated with a decrease in the phosphorylation of c-Jun and c-Jun N-terminal kinase proteins and in nuclear factor-kappa B (NFκB) that regulate inflammation (<xref ref-type="bibr" rid="B130">Lonergan et al., 2004</xref>; <xref ref-type="bibr" rid="B194">Shi et al., 2016</xref>). EPA dietary supply attenuates the activation of microglial cells and astrocytes triggered by an intracerebral IL-1β administration and increases the production of IL-10 in the hippocampus in rats (<xref ref-type="bibr" rid="B200">Song and Horrobin, 2004</xref>; <xref ref-type="bibr" rid="B201">Song et al., 2008</xref>; <xref ref-type="bibr" rid="B66">Dong et al., 2017</xref>). Following dietary DHA supplementation, there is an increase of DHA in the phospholipid and free fatty acid fractions. However, only the unesterified DHA is necessary to attenuate neuroinflammation. Nevertheless, the DHA phospholipid pool is an important source of unesterified DHA (<xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>). On the contrary, in mice, an n-3 PUFA deficiency from the first day of gestation to weaning increases the expression of pro-inflammatory markers in the hippocampus and an alteration in the motility and the phenotype of microglial cells and alters synaptic plasticity (<xref ref-type="bibr" rid="B119">Lafourcade et al., 2011</xref>; <xref ref-type="bibr" rid="B137">Madore et al., 2014</xref>; <xref ref-type="bibr" rid="B213">Thomazeau et al., 2017</xref>). Using the model of intraperitoneal (ip) injection of LPS, we showed that IL-6 expression is strongly induced in n-3 PUFA-deficient mice whereas sickness behavior is down-regulated <italic>via</italic> the impairment of IL-6 signaling in the brain (<xref ref-type="bibr" rid="B144">Mingam et al., 2008</xref>). Moreover, when the deficiency continues in adulthood, it alters GABAergic, dopaminergic and cholinergic neurotransmission (<xref ref-type="bibr" rid="B235">Zimmer et al., 2000</xref>; <xref ref-type="bibr" rid="B2">Aid et al., 2003</xref>; <xref ref-type="bibr" rid="B34">Chalon, 2006</xref>; <xref ref-type="bibr" rid="B120">Larrieu et al., 2014</xref>) and anxiety-related, depressive-like behaviors that can be compared with autistic behavior in adults (<xref ref-type="bibr" rid="B144">Mingam et al., 2008</xref>; <xref ref-type="bibr" rid="B122">Larrieu et al., 2012</xref>; <xref ref-type="bibr" rid="B120">Larrieu et al., 2014</xref>; <xref ref-type="bibr" rid="B97">Hughes et al., 2016</xref>; <xref ref-type="bibr" rid="B138">Manduca et al., 2017</xref>). Following ip injection of LPS, n-3 PUFA-deficient mice display altered hippocampal synaptic plasticity that likely contributes to spatial memory impairment and higher glucocorticoid levels (<xref ref-type="bibr" rid="B59">Delpech et al., 2015b</xref>). On the contrary, an n-3 PUFA dietary supply improves emotional behavior alteration and memory deficit in rats (<xref ref-type="bibr" rid="B200">Song and Horrobin, 2004</xref>; <xref ref-type="bibr" rid="B201">Song et al., 2008</xref>; <xref ref-type="bibr" rid="B66">Dong et al., 2017</xref>), restores social and memory performance altered in autism models and improves depressive symptoms in both mice (<xref ref-type="bibr" rid="B163">Pietropaolo et al., 2014</xref>; <xref ref-type="bibr" rid="B136">Madore et al., 2016</xref>; <xref ref-type="bibr" rid="B224">Weiser et al., 2016</xref>) and rats (<xref ref-type="bibr" rid="B23">Bove et al., 2018</xref>; <xref ref-type="bibr" rid="B147">Morgese et al., 2018</xref>). Of note, n-3 LC-PUFA dietary supplementation attenuates depressive symptoms in depressed patients presenting inflammation (<xref ref-type="bibr" rid="B142">McNamara, 2015</xref>; <xref ref-type="bibr" rid="B167">Rapaport et al., 2016</xref>; <xref ref-type="bibr" rid="B121">Larrieu and Layé, 2018</xref>; <xref ref-type="bibr" rid="B124">Layé et al., 2018</xref>). This protective effect seems to be linked to EPA which could target microglia to reduce neuroinflammation (<xref ref-type="bibr" rid="B17">Bazinet et al., 2019</xref>). n-3 LC-PUFAs could also modulate neuroinflammation through their effect on the HPA axis (<xref ref-type="bibr" rid="B120">Larrieu et al., 2014</xref>; <xref ref-type="bibr" rid="B97">Hughes et al., 2016</xref>; <xref ref-type="bibr" rid="B121">Larrieu and Layé, 2018</xref>). With Alzheimer’s disease, β-amyloid triggers depressive symptoms through neuroinflammatory processes that could be improved by dietary n-3 PUFAs (<xref ref-type="bibr" rid="B23">Bove et al., 2018</xref>; <xref ref-type="bibr" rid="B147">Morgese et al., 2018</xref>). Altogether these data reinforce the importance of n-3 PUFAs as regulators of inflammation and associated depressive symptoms.</p>
<p>Another way to modulate neuroinflammation is to administer n-3 PUFAs directly into the brain or peripherally. Indeed, a 24-hour intracerebroventriculary (icv) DHA brain infusion attenuates hippocampal neuroinflammation initiated by icv LPS in mice (<xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>). In a mouse model of cerebral ischemia, DHA icv administration inhibits NFκB activation and cyclooxygenase-2 (COX-2) expression in the hippocampus (<xref ref-type="bibr" rid="B139">Marcheselli et al., 2003</xref>). Moreover, intrathecal injection of DHA decreases microglial activation, mitogen-activated protein kinase (MAPK) phosphorylation and the production of pro-inflammatory cytokines in the spinal cord of mice (<xref ref-type="bibr" rid="B133">Lu et al., 2013</xref>). In addition, in a model of traumatic brain injury in rats, n-3 PUFA ip injection attenuates microglial-induced inflammation by inhibiting the NFκB pathway (<xref ref-type="bibr" rid="B37">Chen et al., 2017</xref>).</p>
<p>Dietary n-3 LC-PUFA supplementation requires the use of fish oil. However, fish oil may provide confusing factors such as vitamins, for example. Thus, the use of Fat-1 transgenic mice that convert n-6 to n-3 PUFAs through a desaturase from <italic>C. elegans</italic> is a model that enables the elimination of confusing factors provided by the diet (<xref ref-type="bibr" rid="B104">Kang et al., 2004</xref>). Such mice have higher DHA levels in the hippocampus and cortex (<xref ref-type="bibr" rid="B58">Delpech et al., 2015a</xref>; <xref ref-type="bibr" rid="B21">Boudrault et al., 2010</xref>; <xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>). They express less COX-2 (involved in the production of lipid mediators) in the cortex than wild type mice (<xref ref-type="bibr" rid="B21">Boudrault et al., 2010</xref>). They are protected against cognitive deficits induced by ip LPS injection through a decrease in neuroinflammation (<xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>; <xref ref-type="bibr" rid="B58">Delpech et al., 2015a</xref>). This is associated with a decrease in microglial activation (<xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>).</p>
</sec>
<sec id="s2_2_3">
<title>Evidence in <italic>In Vitro</italic> Studies</title>
<p><italic>In vitro</italic> studies have shown that n-3 PUFAs have an inhibitory effect on the production of pro-inflammatory cytokines in microglial cells. Indeed, in the microglial cell line or primary culture microglial cells, DHA prevents LPS-induced NKκB activation and then cytokine production by inhibiting LPS receptor presentation and decreases the oxidative stress, nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) expression (<xref ref-type="bibr" rid="B55">De Smedt-Peyrusse et al., 2008</xref>; <xref ref-type="bibr" rid="B132">Lu et al., 2010</xref>; <xref ref-type="bibr" rid="B4">Antonietta Ajmone-Cat et al., 2012</xref>; <xref ref-type="bibr" rid="B162">Pettit et al., 2013</xref>; <xref ref-type="bibr" rid="B36">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="B47">Corsi et al., 2015</xref>; <xref ref-type="bibr" rid="B75">Fourrier et al., 2017</xref>; <xref ref-type="bibr" rid="B99">Inoue et al., 2017</xref>;). Moreover, DHA prevents LPS-induced MAPK phosphorylation (MAPK pathway playing essential roles in the expression of inflammatory molecules) and induces peroxisome proliferator-activated receptor (PPAR)-γ nuclear translocation that exerts anti-inflammatory effects (<xref ref-type="bibr" rid="B4">Antonietta Ajmone-Cat et al., 2012</xref>). Of interest, EPA also affects the production of TNF-α, IL-6 and NO by inhibiting NFκB phosphorylation <italic>via</italic> sirtuin-1 (SIRT-1) (<xref ref-type="bibr" rid="B146">Moon et al., 2007</xref>; <xref ref-type="bibr" rid="B36">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="B99">Inoue et al., 2017</xref>). It is likely that DHA attenuates the inflammatory response in LPS-activated microglia by remodeling lipid bodies that are dynamic organelles in which DHA is incorporated and by altering their interplay with mitochondria and other associated organelles (<xref ref-type="bibr" rid="B216">Tremblay et al., 2016</xref>). In addition, DHA and EPA are able to enhance myelin or amyloid β (Aβ) peptide phagocytosis that is associated with a shift in microglial polarization toward the beneficial M2 phenotype and to a decrease in pro-inflammatory cytokine production (<xref ref-type="bibr" rid="B95">Hjorth et al., 2013</xref>; <xref ref-type="bibr" rid="B36">Chen et al., 2014</xref>).</p>
<p>This modulation of neuroinflammation induced by n-3 LC-PUFA supply is attributed, in part, to SPM synthesis (<xref ref-type="bibr" rid="B11">Barden et al., 2016</xref>). In the various phases of inflammatory response, prostaglandins, leukotrienes and thromboxane are synthesized first (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>). They permit the propagation of inflammation. They also stimulate the synthesis of SPMs with pro-resolutive properties (<xref ref-type="bibr" rid="B127">Levy et al., 2001</xref>; <xref ref-type="bibr" rid="B189">Serhan and Savill, 2005</xref>).</p>
<fig id="f1" position="float">
<label>Figure 1</label>
<caption>
<p>Molecular events implicated in inflammation and the resolution of inflammation. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; IL, interleukin; TGF, transforming growth factor; TNF, tumor necrosis factor.</p>
</caption>
<graphic xlink:href="fphar-10-01022-g001"></graphic>
</fig>
</sec>
</sec>
<sec id="s2_3">
<title>n-3 PUFA-Derived SPMs and Their Synthesis Pathway</title>
<p>Many of the n-3 PUFA-derived immunomodulators that orchestrate the inflammatory response are lipids (<xref ref-type="bibr" rid="B67">Doyle et al., 2018</xref>). Some of them are involved in the regulation of inflammation (prostaglandins, thromboxanes, leukotrienes, etc.) and others are implicated in the resolution of inflammation (resolvins, protectins and maresins). There is a temporal shift in the lipid mediator synthesis from the initiation of inflammation to the resolution that allows the formation of different lipid mediators at different times (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>). Here we have focused on SPMs, which are of great interest since they permit a return to homeostasis (<xref ref-type="bibr" rid="B184">Serhan et al., 2015</xref>; <xref ref-type="bibr" rid="B206">Sugimoto et al., 2016</xref>). Charles N. Serhan first identified these SPMs at the periphery and characterized their anti-inflammatory and pro-resolutive properties (<xref ref-type="bibr" rid="B186">Serhan et al., 2000</xref>). SPMs actively orchestrate and finely tune the inflammatory response. They decrease pro-inflammatory cytokines and increase anti-inflammatory cytokines, accelerate the phagocytosis of cellular debris and dead cells without immune suppression. A failure in the resolution of inflammation is detrimental for tissue and contributes to a chronic inflammatory response.</p>
</sec>
</sec>
<sec id="s3">
<title>Biosynthesis and Biological Roles of n-3 PUFA-Derived SPMs</title>
<sec id="s3_1">
<title>Biosynthesis of n-3 PUFA-Derived SPMs</title>
<p>Free (unesterified) n-3 LC-PUFAs are released from membrane phospholipids through the action of phospholipases A2 (PLA2) in response to stimulation. DHA is hydrolyzed by calcium independent PLA2 (iPLA2) from phospholipids and plasmenylethanolamine-PLA2 from plasmalogens (<xref ref-type="bibr" rid="B72">Farooqui and Horrocks, 2006</xref>). After this step, n-3 LC-PUFAs undergo an enzymatic conversion to generate SPMs (<xref ref-type="fig" rid="f2"><bold>Figures 2</bold></xref> and <xref ref-type="fig" rid="f3"><bold>3</bold></xref>).</p>
<fig id="f2" position="float">
<label>Figure 2</label>
<caption>
<p>Main synthesis pathway of n-3 long-chain PUFA-derived lipid mediators. ALX/FpR2, lipoxin A4 receptor/formyl peptide receptor 2; BLT1, Leukotriene B4 receptor 1; ChemR23, chemokine-like receptor 1; COX-2, cyclooxygenase-2; CYP450, monoxygenases cytochrome P450; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GPR, G protein-coupled receptor; HDHA, hydroxy-docosahexaenoic acid; HEPE, hydroxy-eicosapentaenoic acid; HpDHA, hydroperoxyl-docosahexaenoic acid; HpEPE, hydroperoxy-eicosapentaenoic acid; LOX, lipoxygenases; PLA2, phospholipase A2.</p>
</caption>
<graphic xlink:href="fphar-10-01022-g002"></graphic>
</fig>
<fig id="f3" position="float">
<label>Figure 3</label>
<caption>
<p>Biochemical structures of the main n-3 long-chain PUFA-derived lipid mediators. DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HpDHA, hydroperoxyl-docosahexaenoic acid; HpEPE, hydroperoxy-eicosapentaenoic acid; Mar1, maresin 1; NPD1, neuroproetectin D1; RvD1, resolvin D1; RvE1, resolvin E1. (<xref ref-type="bibr" rid="B188">Serhan and Petasis, 2011</xref>; <xref ref-type="bibr" rid="B184">Serhan et al., 2015</xref>)</p>
</caption>
<graphic xlink:href="fphar-10-01022-g003"></graphic>
</fig>
<p>n-3 PUFA-derived SPMs are synthesized mainly from DHA and EPA <italic>via</italic> COX-2, lipoxygenases (LOX) and CYP450 monoxygenases (CYP450). In the brain, 15-LOX, 12/15-LOX and 5-LOX are the most abundant LOX and are widely distributed, suggesting the potential production of SPMs (<xref ref-type="bibr" rid="B191">Shalini et al., 2017</xref>). They are expressed in the second step of inflammation in the hippocampus (<xref ref-type="bibr" rid="B50">Czapski et al., 2010</xref>; <xref ref-type="bibr" rid="B18">Birnie et al., 2013</xref>). 15-LOX is involved in neurodegeneration and neurotoxicity due to the increased oxidative stress it generates in models of Alzheimer’s disease (<xref ref-type="bibr" rid="B164">Pratico et al., 2004</xref>; <xref ref-type="bibr" rid="B220">Wang et al., 2015</xref>) and brain ischemia (<xref ref-type="bibr" rid="B232">Yigitkanli et al., 2017</xref>). However, it is also implicated in neuroprotection (<xref ref-type="bibr" rid="B207">Sun et al., 2015</xref>). Indeed, it increases the production of 12-HETE and 15-HETE that promote the activation of PPARγ that is neuroprotective through its anti-inflammatory properties. The inhibition of 15-LOX induces hippocampus-dependent cognitive alterations (<xref ref-type="bibr" rid="B191">Shalini et al., 2017</xref>). Indeed, it prevented long term potentiation, a major molecular mechanism that describes the strengthening of synapses and underlies learning and memory. Moreover, 15-LOX deletion drastically decreases SPM production in the brain while SPMs also modulate synaptic plasticity (<xref ref-type="bibr" rid="B159">Park et al., 2011</xref>; <xref ref-type="bibr" rid="B191">Shalini et al., 2017</xref>). In the brain, the inducible COX-2 is activated <italic>via</italic> an NFκB pathway (<xref ref-type="bibr" rid="B149">Nadjar et al., 2005</xref>). COX-2 catalyzes the first step of the synthesis of prostaglandins and thromboxanes derived from n-6 PUFAs that contribute to the initiation of inflammation (<xref ref-type="bibr" rid="B54">Davidson et al., 2001</xref>; <xref ref-type="bibr" rid="B178">Salinas et al., 2007</xref>; <xref ref-type="bibr" rid="B69">Engstrom et al., 2012</xref>). COX-2 also produces hydroxyl fatty acids from DHA in both an aspirin-dependent and aspirin-independent manner (<xref ref-type="bibr" rid="B187">Serhan et al., 2002</xref>; <xref ref-type="bibr" rid="B154">Oh et al., 2011</xref>; <xref ref-type="bibr" rid="B81">Gabbs et al., 2015</xref>; <xref ref-type="bibr" rid="B151">Nebert, 2017</xref>). In response to LPS, COX-2 is rapidly expressed in the hippocampus (<xref ref-type="bibr" rid="B50">Czapski et al., 2010</xref>; <xref ref-type="bibr" rid="B172">Rey et al., 2019</xref>). Inhibition of COX-2 delays resolution of acute inflammation (<xref ref-type="bibr" rid="B179">Schwab et al., 2007</xref>). CYP450s play a complex role in inflammation by producing n-6 PUFA-derived bioactive mediators such as epoxides that are anti-inflammatory in monocytes and macrophages (<xref ref-type="bibr" rid="B26">Bystrom et al., 2011</xref>; <xref ref-type="bibr" rid="B74">Fleming, 2011</xref>; <xref ref-type="bibr" rid="B152">Nebert et al., 2013</xref>; <xref ref-type="bibr" rid="B83">Gilroy et al., 2016</xref>).</p>
<p>DHA is the precursor of resolvins D1-6 (RvD1-6), neuroprotectin D1 (NPD1) and maresins 1–2 (Mar1-2) which all have pro-resolutive and anti-inflammatory properties (<xref ref-type="bibr" rid="B204">Spite and Serhan, 2010</xref>; <xref ref-type="bibr" rid="B88">Halade et al., 2018</xref>). RvD1-6 are synthesized from DHA but RvD1 is the most studied because it has powerful anti-inflammatory and pro-resolutive properties. DHA is converted into monohydroxy DHA, 17-hydroxy docosahexaenoic acid (17-HDHA) by acetylated COX-2, CYP450 and 15-LOX (<xref ref-type="bibr" rid="B11">Barden et al., 2016</xref>; <xref ref-type="bibr" rid="B88">Halade et al., 2018</xref>) and then into RvD1 by 5-LOX (<xref ref-type="bibr" rid="B209">Sun et al., 2007</xref>; <xref ref-type="bibr" rid="B169">Recchiuti, 2013</xref>). DHA is also converted into di-hydroxy-DHA, termed protectin D1 (PD1) or neuroprotectin D1 (NPD1) when produced in the central nervous system by 5- and 15-LOX (<xref ref-type="bibr" rid="B96">Hong et al., 2003</xref>; <xref ref-type="bibr" rid="B8">Aursnes et al., 2014</xref>; <xref ref-type="bibr" rid="B116">Kuda, 2017</xref>; <xref ref-type="bibr" rid="B67">Doyle et al., 2018</xref>). Acetylated COX-2 permits the synthesis of aspirin-triggered PD1 (AT-PD1) which has powerful protective effects (<xref ref-type="bibr" rid="B16">Bazan et al., 2012</xref>). DHA is transformed into Mar 1-2 by 12/15-LOX <italic>via</italic> the synthesis of 14-HDHA (<xref ref-type="bibr" rid="B190">Serhan et al., 2009</xref>; <xref ref-type="bibr" rid="B11">Barden et al., 2016</xref>; <xref ref-type="bibr" rid="B88">Halade et al., 2018</xref>).</p>
<p>EPA is the precursor of resolvins E1 (RvE1), E2 and E3 that have many biological roles (<xref ref-type="bibr" rid="B186">Serhan et al., 2000</xref>; <xref ref-type="bibr" rid="B173">Rey et al., 2016</xref>; <xref ref-type="bibr" rid="B88">Halade et al., 2018</xref>). It is converted by aspirin-triggered acetylated COX-2 or CYP450 into 18R-hydroxyeicosapentaenoic acid (18R-HEPE), that is transformed into RvE1 or E2 by 5-LOX (<xref ref-type="bibr" rid="B155">Ohira et al., 2010</xref>; <xref ref-type="bibr" rid="B11">Barden et al., 2016</xref>) or into RvE3 by 15-LOX (<xref ref-type="bibr" rid="B101">Isobe et al., 2012</xref>).</p>
<p>Little is known concerning the pharmacokinetics and dynamics of oxylipins. They are synthesized <italic>in situ</italic>, reinforcing the importance of the fatty acid composition of the brain. They are not stored, but produced on demand and they are unstable, being rapidly metabolized.</p>
<p>The structure of all derivatives is highly preserved in the evolution from fish to humans suggesting their great bioactive role in all organ systems. Dysfunction of SPM production can be due to insufficient EPA and DHA supply leading to inadequate production of SPMs or to the polymorphism of the enzymes involved in their synthesis or to a defect in the binding of SPMs to their receptors (<xref ref-type="bibr" rid="B206">Sugimoto et al., 2016</xref>). In humans, reduced SPM production is associated with chronicity and the magnitude of persistent inflammation. SPMs have multiple biological roles in the maintenance of homeostasis.</p>
</sec>
<sec id="s3_2">
<title>Biological Roles of DHA-Derived SPMs</title>
<p>In human serum, the DHA-derivatives represent 30.7% of the identified SPMs (<xref ref-type="bibr" rid="B45">Colas et al., 2014</xref>; <xref ref-type="bibr" rid="B185">Serhan et al., 2018</xref>). RvD1, PD1 and Mar1 were detected at 30.9 pg/mL, 5.6 pg/mL and 21.2 pg/mL, respectively. They act in the nanomolar or picomolar range as compared with DHA and EPA acting in the micromolar range (<xref ref-type="bibr" rid="B131">López-Vicario et al., 2016</xref>; <xref ref-type="bibr" rid="B44">Clària et al., 2017</xref>; <xref ref-type="bibr" rid="B181">Serhan, 2017a</xref>; <xref ref-type="bibr" rid="B219">Wang and Colgan, 2017</xref>; <xref ref-type="bibr" rid="B176">Rosenthal et al., 2018</xref>).</p>
<sec id="s3_2_1">
<title>Resolvins</title>
<p>RvDs have been identified in mice peritoneal exudates (<xref ref-type="bibr" rid="B187">Serhan et al., 2002</xref>). They have many properties at the periphery: protection against bacterial infection, prevention of leucocyte infiltration, inhibition of the production of cytokines, etc. (<xref ref-type="bibr" rid="B203">Spite et al., 2009</xref>; <xref ref-type="bibr" rid="B188">Serhan and Petasis, 2011</xref>; <xref ref-type="bibr" rid="B38">Chiang et al., 2012</xref>; <xref ref-type="bibr" rid="B52">Dalli et al., 2013a</xref>; <xref ref-type="bibr" rid="B225">Winkler et al., 2016</xref>). RvD1 and its precursor metabolites have been detected in the brain.</p>
<p><italic>In vitro</italic>, 17-HDHA has been found in glial cells after DHA and inflammatory stimulus (<xref ref-type="bibr" rid="B96">Hong et al., 2003</xref>). <italic>In vivo</italic>, RvD1 has been identified in mouse brain following cerebral ischemia (<xref ref-type="bibr" rid="B139">Marcheselli et al., 2003</xref>). Intravenous (iv) DHA injection increases RvD1 levels in rats suggesting the conversion of DHA into RvD1 (<xref ref-type="bibr" rid="B148">Mulik et al., 2016</xref>). RvD1 acts through the lipoxin A4 receptor/formyl peptide receptor 2 (ALX/Fpr2) in rodents and the G protein coupling receptor 32 (GPR32) in humans (<xref ref-type="bibr" rid="B169">Recchiuti, 2013</xref>) in the picomolar range but induces biological effects in the nanomolar range (<xref ref-type="bibr" rid="B209">Sun et al., 2007</xref>; <xref ref-type="bibr" rid="B114">Krishnamoorthy et al., 2010</xref>). An overexpression of ALX/Fpr2 or GPR32 increases in phagocytosis by macrophages whereas their deletion decreases the phagocytosis response (<xref ref-type="bibr" rid="B161">Perretti et al., 2002</xref>; <xref ref-type="bibr" rid="B114">Krishnamoorthy et al., 2010</xref>; <xref ref-type="bibr" rid="B46">Cooray et al., 2013</xref>). RvD1 regulates the expression of specific micro-RNA (miR) to control the intensity and the length of inflammation <italic>via</italic> the regulation of target genes such as inflammatory cytokine genes (<xref ref-type="bibr" rid="B78">Fredman and Serhan, 2011</xref>; <xref ref-type="bibr" rid="B170">Recchiuti et al., 2011</xref>; <xref ref-type="bibr" rid="B173">Rey et al., 2016</xref>; <xref ref-type="bibr" rid="B19">Bisicchia et al., 2018</xref>). RvD1 increases the expression of miR-21, miR-146b and miR-219 and decreases the expression of miR-208a in macrophages and peritoneal exudates in mice (<xref ref-type="bibr" rid="B170">Recchiuti et al., 2011</xref>; <xref ref-type="bibr" rid="B113">Krishnamoorthy et al., 2012</xref>). RvD1 modulates miR-155, miR-146, miR-21 and miR-219 in microglial cells (<xref ref-type="bibr" rid="B173">Rey et al., 2016</xref>). These miRs have different biological roles: miR-21 is essential to the production of anti-inflammatory cytokine IL-10, miR-146 regulates the transcription of cytokines, chemokines and their receptor, miR-219 decreases the transcription of TNF-α and miR-208a regulates the activation of NFkB (<xref ref-type="bibr" rid="B170">Recchiuti et al., 2011</xref>).</p>
<p>RvD1 controls the inflammatory response in many animal models <italic>via</italic> its anti-inflammatory and pro-resolutive properties. In rats, endogenous RvD1 levels decrease at the beginning of inflammation and then increase during the resolution phase (<xref ref-type="bibr" rid="B208">Sun et al., 2014</xref>). Recent studies describe the anti-inflammatory properties of RvD1 in microglia and astrocyte cell cultures (<xref ref-type="bibr" rid="B1">Abdelmoaty et al., 2013</xref>; <xref ref-type="bibr" rid="B128">Li et al., 2014</xref>; <xref ref-type="bibr" rid="B173">Rey et al., 2016</xref>). Indeed, in BV2 microglia cell culture, RvD1 promotes the IL-4-induced M2 phenotype (<xref ref-type="bibr" rid="B128">Li et al., 2014</xref>) and inhibits LPS-induced pro-inflammatory cytokines (<xref ref-type="bibr" rid="B173">Rey et al., 2016</xref>). In astrocyte cell culture, RvD1 attenuates LPS-induced TNF-α (<xref ref-type="bibr" rid="B1">Abdelmoaty et al., 2013</xref>). <italic>In vivo</italic>, in a model of remote damage, Bisicchia et al. recently show in rats that RvD1 promotes functional recovery and reduces neuroinflammation <italic>via</italic> miRs (<xref ref-type="bibr" rid="B19">Bisicchia et al., 2018</xref>).</p>
<sec id="s3_2_1_1">
<title>Biological Roles of RvD1 in Humans</title>
<p>The effect of RvD1 has been studied in patients suffering from Alzheimer’s disease. This pathology is characterized by an increase in microglial activation and in pro-inflammatory cytokine production in the brain (<xref ref-type="bibr" rid="B85">Griffin et al., 1989</xref>; <xref ref-type="bibr" rid="B27">Cagnin et al., 2001</xref>). Interestingly, RvD1 levels in the cerebrospinal fluid are positively correlated with the enhancement of cognitive functions of patients with dementia (<xref ref-type="bibr" rid="B220">Wang et al., 2015</xref>). Indeed, RvD1 may be involved in Aβ phagocytosis. This has been shown <italic>in vitro</italic> in macrophages isolated from Alzheimer’s patients (<xref ref-type="bibr" rid="B145">Mizwicki et al., 2013</xref>; <xref ref-type="bibr" rid="B70">Famenini et al., 2017</xref>). Thus the decrease in RvD1 levels in Alzheimer patients’ brains could contribute to the evolution of the disease.</p>
</sec>
<sec id="s3_2_1_2">
<title>Biological Roles of RvD1 in Rodents</title>
<p>RvD1 attenuates the pro-inflammatory status in the central nervous system. Indeed, an intrathecal injection of 17R-HDHA decreases TNF-α release in the spinal cord in rats (<xref ref-type="bibr" rid="B1">Abdelmoaty et al., 2013</xref>). Orr et al. show that icv injection of 17S-HDHA into mice decreases the expression of hippocampal pro-inflammatory cytokines IL-1β and TNF-α induced by LPS acute icv injection (<xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>). However, these authors detected NPD1 but did not detect RvD1, suggesting that the effect of 17S-HDHA was rather due to the conversion of 17S-HDHA into NPD1. RvD1 is also able to stimulate phagocytosis in macrophages (<xref ref-type="bibr" rid="B177">Rossi et al., 2015</xref>). Indeed, DHA and RvD1 induce the polarization of macrophages toward an M2 phagocytic phenotype in mice (<xref ref-type="bibr" rid="B215">Titos et al., 2011</xref>).</p>
<p>Studies have highlighted the protective role of RvD1 in the occurrence of cognitive deficits. Terrando et al. showed that an ip injection of 17-HDHA restores transmission and synaptic plasticity and prevents astrogliosis and cognitive decline in a systemic inflammation model in mice (<xref ref-type="bibr" rid="B212">Terrando et al., 2013</xref>). Conversely, an inhibition of 15-LOX, associated with a decrease in RvD1, alters synaptic plasticity and working memory as demonstrated in rats (<xref ref-type="bibr" rid="B191">Shalini et al., 2017</xref>). RvD1 plays also a role during the recovery phase following cerebral ischemia. Indeed, the precursor of 17-HDHA, 17-hydroperoxy docosahexaenoic acid (17-HpDHA), accumulates in the hippocampus of mice (<xref ref-type="bibr" rid="B139">Marcheselli et al., 2003</xref>). An ip chronic administration of 17R-HDHA synthesized by acetylated COX-2, prevents cognitive deficits and attenuates motor disorders but doesn’t ameliorate microglial activation and sleep quality in mice (<xref ref-type="bibr" rid="B90">Harrison et al., 2015</xref>). Moreover, Fat-1 mice that have more brain n-3 LC-PUFAs, have higher hippocampus RvD1 levels, associated with less cognitive deficits, a better neuronal survival, a decrease in astrocyte and microglial activation and a reduction in pro-inflammatory status following brain ischemia (<xref ref-type="bibr" rid="B135">Luo et al., 2014</xref>; <xref ref-type="bibr" rid="B58">Delpech et al., 2015a</xref>).</p>
<p>Studies have also highlighted the protective role of resolvins in the depressive-like behavior in rodents. Some of them have been recently reported by Furuyashiki et al. (<xref ref-type="bibr" rid="B80">Furuyashiki et al., 2019</xref>). An icv injection of RvD1, D2, E1, E2, or E3 significantly decreases LPS-induced depressive-like behavior in mice (<xref ref-type="bibr" rid="B61">Deyama et al., 2017</xref>; <xref ref-type="bibr" rid="B62">Deyama et al., 2018a</xref>; <xref ref-type="bibr" rid="B63">Deyama et al., 2018b</xref>). Moreover, the occurrence of depressive-like behavior associated with pain can also be prevented by an intrathecal injection of 17R-HDHA that is associated with the decrease of pain perception and a restoration of dopamine and glutamate levels in the brain both in rats (<xref ref-type="bibr" rid="B1">Abdelmoaty et al., 2013</xref>) and mice (<xref ref-type="bibr" rid="B110">Klein et al., 2014</xref>). RvD1 and D2 have also positive effects in chronic mild stress-induced depression and in post-myocardial infarct depression in rats (<xref ref-type="bibr" rid="B82">Gilbert et al., 2014</xref>) and mice (<xref ref-type="bibr" rid="B100">Ishikawa et al., 2017</xref>).</p>
</sec>
<sec id="s3_2_1_3">
<title>Biological Roles of RvD1 in In Vitro Models</title>
<p>The effects of RvD1 were tested on different brain cells. In microglial cells, RvD1 potentiates the effect of the anti-inflammatory cytokine IL-4 in the activation of M2 phenotype of microglia (<xref ref-type="bibr" rid="B128">Li et al., 2014</xref>). Moreover, we showed that RvD1 decreases LPS-induced pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) gene expression in microglial BV2 cells <italic>via</italic> the modulation of miRs (<xref ref-type="bibr" rid="B173">Rey et al., 2016</xref>). This suggests its pro-resolutive activity in microglia. In astrocytes, RvD1 decreases TNF-α release induced by LPS injection (<xref ref-type="bibr" rid="B1">Abdelmoaty et al., 2013</xref>). In neurons from spinal nods, RvD1 increases neurite outgrowth (<xref ref-type="bibr" rid="B193">Shevalye et al., 2015</xref>). All these studies suggest that RvD1 can play a central role in the regulation of neuroinflammatory pathologies.</p>
<p>Other D resolvins have been identified in rodent brain: RvD2, RvD4 and RvD5 (<xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>; <xref ref-type="bibr" rid="B91">Hashimoto et al., 2015</xref>; <xref ref-type="bibr" rid="B225">Winkler et al., 2016</xref>). RvD2 limits the activation of microglial cells and inhibits the TLR4/NFκB pathway (<xref ref-type="bibr" rid="B214">Tian et al., 2015</xref>). Moreover, chronic intrathecal RvD2 injection prevents the behavioral alterations induced by LPS central injection (<xref ref-type="bibr" rid="B214">Tian et al., 2015</xref>). It also prevents depressive-like behavior induced by ip LPS injection by regulating mammalian target of rapamycin complex 1 (mTORC1) complex (<xref ref-type="bibr" rid="B61">Deyama et al., 2017</xref>). RvD5 level is decreased in the brain of Alzheimer’s disease patients but its role has not yet been identified (<xref ref-type="bibr" rid="B234">Zhu et al., 2016</xref>).</p>
</sec>
</sec>
<sec id="s3_2_2">
<title>Neuroprotectin</title>
<p>Di-hydroxy-DHA termed protection D1 (PD1) has been identified in blood, peritoneal neutrophils and neuroprotectin D1 (NPD1) in the brain in response to zymosan in mice (<xref ref-type="bibr" rid="B96">Hong et al., 2003</xref>). Marcheselli et al. have measured NPD1 production in mice hippocampus following brain ischemia (<xref ref-type="bibr" rid="B139">Marcheselli et al., 2003</xref>). One receptor for NPD1 has recently been identified as GPR37 (<xref ref-type="bibr" rid="B165">Qu and Caterina, 2018</xref>). NPD1 inhibits the oxidative stress in retinal epithelial cells and stimulates their proliferation (<xref ref-type="bibr" rid="B15">Bazan, 2009</xref>; <xref ref-type="bibr" rid="B28">Calandria and Bazan, 2010</xref>). NPD1 is also able to inhibit neovascularization <italic>via</italic> microglial cell ramification in mice (<xref ref-type="bibr" rid="B192">Sheets et al., 2013</xref>). In the central nervous system of mice, the NPD1 level greatly increases in the hippocampus following brain ischemia or acute central LPS injection (<xref ref-type="bibr" rid="B139">Marcheselli et al., 2003</xref>; <xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>). Hence, NPD1 limits neutrophil infiltration, inhibits NFκB and then decreases pro-inflammatory gene expression (<xref ref-type="bibr" rid="B139">Marcheselli et al., 2003</xref>; <xref ref-type="bibr" rid="B16">Bazan et al., 2012</xref>; <xref ref-type="bibr" rid="B231">Yao et al., 2013</xref>). NPD1 levels decrease in the hippocampus of Alzheimer’s disease patients (<xref ref-type="bibr" rid="B134">Lukiw et al., 2005</xref>). It plays a role in cellular survival <italic>via</italic> anti-apoptotic protein induction and attenuates pro-inflammatory responses following Aβ exposure <italic>via</italic> NFκB regulation (<xref ref-type="bibr" rid="B134">Lukiw et al., 2005</xref>; <xref ref-type="bibr" rid="B14">Bazan, 2008</xref>; <xref ref-type="bibr" rid="B7">Asatryan and Bazan, 2017</xref>).</p>
</sec>
<sec id="s3_2_3">
<title>Maresins</title>
<p>Mar1 has been identified in mice peritoneal macrophages (<xref ref-type="bibr" rid="B53">Dalli et al., 2013b</xref>; <xref ref-type="bibr" rid="B190">Serhan et al., 2009</xref>). Its receptor has not been identified yet (<xref ref-type="bibr" rid="B234">Zhu et al., 2016</xref>). Mar1 is involved in the resolution of inflammation, prevents neutrophil infiltration, and increases the phagocytosis of apoptotic neutrophils by macrophages in a peritonitis murine model (<xref ref-type="bibr" rid="B190">Serhan et al., 2009</xref>). In a murine model of colitis, Mar1 decreases the expression of pro-inflammatory cytokines by inhibiting the NFκB pathway and activating the M2 phenotype in macrophages (<xref ref-type="bibr" rid="B140">Marcon et al., 2013</xref>). Mar1 and its precursor 14-HDHA have recently been identified in the hippocampus of mice (<xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>). In <italic>post-mortem</italic> brain of Alzheimer’s disease patients, the Mar1 level is decreased (<xref ref-type="bibr" rid="B234">Zhu et al., 2016</xref>). In this pathology, its role is to stimulate Aβ plaque phagocytosis by microglial cells and to decrease inflammatory marker levels. Hence, Mar1 may play an important role in the pathogenesis of Alzheimer’s disease (<xref ref-type="bibr" rid="B234">Zhu et al., 2016</xref>). In cerebral ischemia in mice, Mar1 icv injection decreases inflammation and mitochondrial damage and also reduces neurological deficits <italic>via</italic> activation of SIRT-1 signaling (<xref ref-type="bibr" rid="B227">Xian et al., 2016</xref>; <xref ref-type="bibr" rid="B226">Xian et al., 2019</xref>). After spinal cord injury in mice, iv injection of Mar1 promotes resolution of inflammation (reducing pro-inflammatory cytokines, silencing pro-inflammatory signaling cascades and enhancing the M2 repair macrophage phenotype) and functional recovery (<xref ref-type="bibr" rid="B76">Francos-Quijorna et al., 2017</xref>). Mar1 also decreases <italic>in vitro</italic> neuronal death (<xref ref-type="bibr" rid="B234">Zhu et al., 2016</xref>).</p>
</sec>
</sec>
<sec id="s3_3">
<title>Biological Roles of EPA-Derived SPMs</title>
<p>RvE1, and its precursor 18-HEPE, have been detected in the hippocampus of rats (<xref ref-type="bibr" rid="B35">Chen et al., 2011</xref>) and mice (<xref ref-type="bibr" rid="B156">Orr et al., 2013</xref>; <xref ref-type="bibr" rid="B195">Siegert et al., 2017</xref>). In human serum, the EPA-derivatives represent 25.9% of the identified SPMs (<xref ref-type="bibr" rid="B45">Colas et al., 2014</xref>; <xref ref-type="bibr" rid="B185">Serhan et al., 2018</xref>).</p>
<p>RvE1 has been initially identified in mouse exudates (<xref ref-type="bibr" rid="B186">Serhan et al., 2000</xref>). RvE1 directly binds to its receptor ChemR23 or CMKLR1 (chemokine-like receptor 1) (<xref ref-type="bibr" rid="B155">Ohira et al., 2010</xref>). It is also a partial agonist of LTB4 receptor (BLT1) (<xref ref-type="bibr" rid="B6">Arita et al., 2007</xref>). In the central nervous system, ChemR23 has been identified in the prefrontal cortex, hippocampus and brainstem (<xref ref-type="bibr" rid="B86">Guo et al., 2012</xref>), in microglial cells (<xref ref-type="bibr" rid="B84">Graham et al., 2009</xref>; <xref ref-type="bibr" rid="B173">Rey et al., 2016</xref>) and in neurons (<xref ref-type="bibr" rid="B230">Xu et al., 2010</xref>). It is highly expressed in neurons, in microglial cells and in astrocytes in the <italic>post-mortem</italic> hippocampus of Alzheimer’s patient brain (<xref ref-type="bibr" rid="B220">Wang et al., 2015</xref>). This increase could be due to a compensatory mechanism to counter-balance the decrease in RvE1 in such patients (<xref ref-type="bibr" rid="B220">Wang et al., 2015</xref>). <italic>In vitro</italic>, RvE1 plays also a direct role in microglial cells by inhibiting microglial activation and pro-inflammatory cytokine release (<xref ref-type="bibr" rid="B229">Xu et al., 2013</xref>; <xref ref-type="bibr" rid="B173">Rey et al., 2016</xref>). RvE1 and its precursor, 18R-HEPE, exert anti-inflammatory and anti-apoptotic properties (<xref ref-type="bibr" rid="B92">Hecker et al., 2018</xref>). Indeed, they restore mitochondrial dysfunction induced by inflammation in mononuclear blood cells. <italic>In vivo</italic>, RvE1 modulates the inflammatory profile and microglial activation in mice (<xref ref-type="bibr" rid="B229">Xu et al., 2013</xref>; <xref ref-type="bibr" rid="B90">Harrison et al., 2015</xref>). Intraperitoneal injection of RvE1 also modulates inflammation (by reducing Il-1β, Il-6 and IL-10 levels in the prefrontal cortex) and decreases the measures of Aβ pathology in a murine model of Alzheimer’s disease (<xref ref-type="bibr" rid="B105">Kantarci et al., 2018</xref>). RvE1 and RvE2 centrally administered also reduce the LPS-induced depressive-like behavior through ChemR23 in mice (<xref ref-type="bibr" rid="B63">Deyama et al., 2018b</xref>). RvE1, a total agonist of ChemR23, is more effective than RvE2, which is only a partial agonist of this receptor (<xref ref-type="bibr" rid="B183">Serhan and Chiang, 2013</xref>).</p>
</sec>
</sec>
<sec id="s4">
<title>Regulation of the n-3 PUFA-Derived SPMs</title>
<p>Resolution of inflammation is an active process involving the regulation of the synthesis of numerous mediators in a tightly coordinated manner. The balance between n-3 PUFA-derived SPMs and the pro-inflammatory mediators determines the duration of the inflammatory response and the timing of resolution (<xref ref-type="bibr" rid="B77">Fredman et al., 2017</xref>).</p>
<sec id="s4_1">
<title>Regulation of the n-3 PUFA-Derived SPMs by PUFA Consumption</title>
<p>We have previously shown that PUFA consumption leads to modifications in PUFA levels in the brain. The PUFA derivative levels and their biosynthetic enzyme expression also depend on dietary PUFAs.</p>
<p>SPM levels in peripheral organs and the brain are modulated by different dietary supplies of PUFAs (<xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>). In humans supplemented with 2.4g/day of n-3 LC-PUFAs for 3 weeks (EPA+DHA), SPM levels are generally found to be between 20 and 200 pg/mL (<xref ref-type="bibr" rid="B141">Mas et al., 2012</xref>). A shorter supplementation period (5 days) also increased DHA- and EPA- derived SPMs in plasma, especially 18-HEPE, RvE1, 17- and 14-HDHA (<xref ref-type="bibr" rid="B12">Barden et al., 2014</xref>). In another study, supplementing patients with a higher fish oil supplement (17.6g/day EPA+DHA) for 24h, only PD1 is detected in the plasma and this increases from 1.0–1.2 pg/mL to 2.7–4.1 pg/mL (<xref ref-type="bibr" rid="B197">Skarke et al., 2015</xref>; <xref ref-type="bibr" rid="B11">Barden et al., 2016</xref>). These differences in SPM levels in human plasma could be due to differences in study design, dose, duration of n-3 fatty acid supplementation and patient characteristics, etc. (<xref ref-type="bibr" rid="B11">Barden et al., 2016</xref>; <xref ref-type="bibr" rid="B39">Chiang and Serhan, 2017</xref>). Moreover, dietary supplementation in DHA (1.7g/j) and EPA (0.6g/j) for 6 months increased the RvD1 released by blood mononuclear cells in Alzheimer’s disease patients as compared with controls (<xref ref-type="bibr" rid="B220">Wang et al., 2015</xref>). Results from intervention studies show that EPA and DHA dietary supplementation increases EPA- and DHA-derived oxylipins although with high inter-individual variances (<xref ref-type="bibr" rid="B157">Ostermann et al., 2017</xref>).</p>
<fig id="f4" position="float">
<label>Figure 4</label>
<caption>
<p>Regulation of n-3 long-chain PUFA-derived SPMs by PUFA consumption and inflammation. IL, interleukine; LPS, lipopolysaccharides; PUFA, polyunsaturated fatty acids; SPM, specialized pro-resolving mediators; TNF, tumor necrosis factor.</p>
</caption>
<graphic xlink:href="fphar-10-01022-g004"></graphic>
</fig>
<p>In animals, a 3-week fish oil supplementation in arthritic mice increases synthesis of n-3 PUFA-derived SPMs associated with a diminished production of pro-inflammatory mediators (<xref ref-type="bibr" rid="B153">Norling et al., 2016</xref>). n-3 PUFA dietary supplementation (140 mg EPA+110 mg DHA/kg animal) in aged rats for 10 weeks enhances the production of lipid mediators derived from DHA and EPA in the cerebral cortex (<xref ref-type="bibr" rid="B91">Hashimoto et al., 2015</xref>). DHA and EPA supply also decreases the n-6 PUFA-derived metabolites (which are mainly pro-inflammatory) and increases the n-3 PUFA-derived metabolites in the plasma and at the periphery both in mice (<xref ref-type="bibr" rid="B9">Balvers et al., 2012</xref>; <xref ref-type="bibr" rid="B125">Lazic et al., 2014</xref>) and rats (<xref ref-type="bibr" rid="B91">Hashimoto et al., 2015</xref>). A diet enriched with fish oil (containing 9% EPA + 9% DHA) for 8 weeks in mice increases plasmatic RvD1 (<xref ref-type="bibr" rid="B193">Shevalye et al., 2015</xref>). In Fat-1 mice, brain EPA increase is accompanied by an increase in EPA-derived HEPEs (<xref ref-type="bibr" rid="B195">Siegert et al., 2017</xref>). Conversely, an n-6 PUFA dietary supply from weaning to 15 weeks of age increases the n-6 PUFA metabolites and decreases the EPA-derived metabolites in the cortex and the plasma of rats (<xref ref-type="bibr" rid="B211">Taha et al., 2016</xref>). Recently, we showed that, in mice, n-3 LC-PUFA supplementation from weaning for 2 months induces n-3 LC-PUFA enrichment in the hippocampus and subsequently an increase in n-3 PUFA-derived SPMs and a decrease in n-6 PUFA-derived mediators (<xref ref-type="bibr" rid="B172">Rey et al., 2019</xref>). Moreover, in response to LPS, n-3 LC-PUFA-deficient mice present a pro-inflammatory lipid mediator profile whereas n-3 LC-PUFA-supplemented mice display an anti-inflammatory profile in the hippocampus (<xref ref-type="bibr" rid="B172">Rey et al., 2019</xref>). Indeed, the consumption of n-3 LC-PUFAs increases the EPA and DHA derivatives. Hashimoto et al. found the same in the cortex of aged rats (<xref ref-type="bibr" rid="B91">Hashimoto et al., 2015</xref>). These results differ from those of Trépanier et al. who found that, in a model of Fat-1 mice, a greater increase in brain DHA induced by dietary supply has no effect on the resolution of inflammation after an icv LPS injection (<xref ref-type="bibr" rid="B217">Trépanier et al., 2018</xref>).</p>
<p>SPM production is also finely tuned by the regulation of the enzymes in their biosynthesis pathway. A 15-week n-3 PUFA-deficient diet increases the COX-2 expression in the prefrontal cortex of rats, suggesting an increase in AA-derived pro-inflammatory mediator levels (<xref ref-type="bibr" rid="B166">Rao et al., 2007</xref>). Conversely, a 15-week n-6 PUFA-deficient diet decreases brain COX-2 expression in rats (<xref ref-type="bibr" rid="B108">Kim et al., 2011</xref>). Interestingly, Taha et al. showed that rats fed on an n-6 PUFA-deficient diet for 15 weeks are protected from an increase in COX-2 observed in LPS-treated n-3 PUFA-deficient animals (<xref ref-type="bibr" rid="B210">Taha et al., 2017</xref>). However, we showed that 2 months’ n-3 LC-PUFA dietary supplementation was not sufficient to modulate COX-2 expression in the brain of mice (<xref ref-type="bibr" rid="B172">Rey et al., 2019</xref>). An n-3 LC-PUFA diet increases 15-LOX expression in the hippocampus without changes in the 5-LOX expression (<xref ref-type="bibr" rid="B81">Gabbs et al., 2015</xref>). The increase in 15-LOX in the brain has also been described following a 15-week n-6 PUFA-deficient diet in rats (<xref ref-type="bibr" rid="B108">Kim et al., 2011</xref>). 15-LOX is responsible for many n-6 and n-3 PUFA derivatives. Those synthesized from AA drastically decrease, and those produced from DHA increase, following a diet enriched in n-3 PUFAs in both mice and rats (<xref ref-type="bibr" rid="B157">Ostermann et al., 2017</xref>; <xref ref-type="bibr" rid="B191">Shalini et al., 2017</xref>; <xref ref-type="bibr" rid="B172">Rey et al., 2019</xref>).</p>
<p>Results on 15-LOX functions on inflammation regulation are conflicting. 15-LOX was initially described as deleterious in neurodegenerative pathologies because it increased the oxidative stress and neuronal degeneration (<xref ref-type="bibr" rid="B164">Pratico et al., 2004</xref>; <xref ref-type="bibr" rid="B40">Chinnici et al., 2007</xref>; <xref ref-type="bibr" rid="B64">Di Meco et al., 2014</xref>; <xref ref-type="bibr" rid="B220">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="B232">Yigitkanli et al., 2017</xref>). It alters the mitochondrial function of neurons and then induces neuronal death (<xref ref-type="bibr" rid="B158">Pallast et al., 2009</xref>). However, recent studies demonstrate the protective role of 15-LOX, particularly in cognition. An increase in its expression is associated with a better working memory (<xref ref-type="bibr" rid="B207">Sun et al., 2015</xref>; <xref ref-type="bibr" rid="B191">Shalini et al., 2017</xref>). Moreover, an increase in 15-LOX expression during cerebral ischemia is essential for the recovery of neurological functions after the ischemic event (<xref ref-type="bibr" rid="B218">Wang et al., 2017</xref>). These results suggest that 15-LOX has a beneficial role in acute inflammation (ischemia, LPS) and is deleterious in chronic inflammation (neurodegenerative pathologies). SPM production is also partly regulated by the availability of free PUFAs that are their precursors. Indeed, PLA2 activity also depends on PUFA dietary supply. An n-6 PUFA-deficient diet increases the iPLA2 that is responsible for the release of DHA from the membranes and a decrease in calcium sensitive cytosolic PLA2 (cPLA2) associated with the hydrolysis of AA from the membranes (<xref ref-type="bibr" rid="B108">Kim et al., 2011</xref>).</p>
<p>Lipid nutrition, to which people are exposed throughout their lives, seems to play a major role in the synthesis of bioactive SPMs.</p>
</sec>
<sec id="s4_2">
<title>Regulation of the n-3 PUFA-Derived SPMs by Inflammation</title>
<p>Numerous studies have highlighted that inflammation modulates lipid mediator synthesis at the periphery and in the brain (<xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>).</p>
<p>In humans, Wang et al. showed that the RvD1 level in the cerebrospinal fluid (CSF) of Alzheimer’s disease patients is positively correlated with cognitive function (<xref ref-type="bibr" rid="B220">Wang et al., 2015</xref>). Moreover, 15-LOX was decreased in the CSF suggesting an alteration of the resolution of inflammation in Alzheimer’s patients.</p>
<p>In rats, brain ischemia increases the production of 5 of mono-, di- and tri-hydroxy-DHA derivatives (<xref ref-type="bibr" rid="B71">Farias et al., 2008</xref>; <xref ref-type="bibr" rid="B93">Hennebelle et al., 2017</xref>). However, LPS icv injection does not impact the RvD1 level (<xref ref-type="bibr" rid="B175">Rosenberger et al., 2004</xref>; <xref ref-type="bibr" rid="B210">Taha et al., 2017</xref>). We have recently shown that, in mice, ip LPS injection modifies the n-6 PUFA derivative profile but not n-3 LC-PUFA derivatives (<xref ref-type="bibr" rid="B172">Rey et al., 2019</xref>).</p>
<p><italic>In vitro</italic>, most studies have been performed on peripheral immune cells. The lipid mediator profile in rodent neutrophils and macrophages changes with macrophage phenotype M1 or M2, or with the inflammatory stimulus in neutrophils (<xref ref-type="bibr" rid="B65">Dieter et al., 2002</xref>). Indeed, M2 macrophages produce more D resolvins, protectins and maresins and less AA-derived pro-inflammatory mediators than M1 macrophages (<xref ref-type="bibr" rid="B51">Dalli and Serhan, 2012</xref>).</p>
<p>Inflammation more drastically alters the expression of biosynthetic enzymes than an n-3 LC-PUFA dietary supply. In rats, traumatic brain injury increases the COX-2, 5-LOX, 15-LOX and CYP450 expression in the hippocampus and cortex, suggesting an alteration of all lipid mediator biosynthesis pathways (<xref ref-type="bibr" rid="B18">Birnie et al., 2013</xref>). LPS also regulates the expression of these enzymes. An icv LPS injection increases COX-2 expression and activity in the brain in mice (<xref ref-type="bibr" rid="B172">Rey et al., 2019</xref>) and rats. Moreover, in <italic>in vitro</italic> human monocytes and dendritic cells, anti-inflammatory cytokines IL-4 or IL-13 increase the production of 15-LOX and decrease the production of 5-LOX (<xref ref-type="bibr" rid="B150">Nassar et al., 1994</xref>; <xref ref-type="bibr" rid="B202">Spanbroek et al., 2001</xref>).</p>
<p>Neuroinflammation also modifies SPM receptor expression. Indeed, we show that LPS increases significantly the expression of RvD1 and RvE1 receptors (ALX/Fpr2 and ChemR23, respectively) in BV-2 microglial cells (<xref ref-type="bibr" rid="B173">Rey et al., 2016</xref>). The increase in ALX/Fpr2 expression was also detected in monocytes, in the hippocampus and in the cortex and in microglial cells in response to an inflammatory stimulus (<xref ref-type="bibr" rid="B114">Krishnamoorthy et al., 2010</xref>; <xref ref-type="bibr" rid="B222">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="B220">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="B87">Guo et al., 2016</xref>). Then, inflammation activates the SPM signaling pathway in the brain to regulate the inflammatory response.</p>
</sec>
</sec>
<sec id="s5">
<title>Human Translation</title>
<p>Several possibilities can be considered to translate the findings described above and then attenuate the inflammatory tone, amplitude and duration of inflammation. The first one is to increase the local production of n-3 LC-PUFA-derived SPMs. We see that dietary means is a good way to modulate the level of the fatty acids from which they are synthesized and then to modify their synthesis. The SPM profile synthesized by each individual could be responsible for the differences in the effects of n-3 PUFA obtained in humans. SPM profiles should be established in patients with different acute and chronic inflammatory pathologies, and in mice under the same conditions to find markers of neuroinflammation in the plasma that can be transposed to humans. Thanks to new technologies in liquid chromatography mass spectrometry (LC-MS/MS), specific mediators produced during physiological and non-physiological conditions should be identified, allowing patient stratification according to disease severity. It could be interesting to determine an individual metabolomic profile to define personalized nutrition (n-3 PUFAs and doses) allowing an increase of n-3 PUFA-derived SPMs in the target tissue. Indeed, there are individual differences in diets and in n-3 PUFA supplementation and also in nutrient metabolism and biological responses to food/nutrients. The aim of personalized nutrition is to increase health using nutrition by delivering specific personalized intervention suited to each individual based on the individual’s nutritional phenotype, metabolic profile, and environmental factors in order to prevent and treat chronic disease. Personalized nutrition can also be applied to healthy people. It is nowadays accessible because of a better understanding of the mechanisms of the effect of nutrition on health and also because of the progress in technologies enabling the identification of specific markers. Personalized nutrition has already shown its efficacy, especially in the Food4Me study involving &gt;1600 participants from 7 European countries and in a systematic review and meta-analysis showing a greater efficacy of personalized nutrition in changing diet than a conventional approach (<xref ref-type="bibr" rid="B33">Celis-Morales et al., 2018</xref>).</p>
<p>The second possibility for taking advantage of research on the resolution of inflammation is to administer exogenous SPMs. Serhan defines a new concept of resolutive pharmacology targeting the development of SPM analogs, resistant to local inactivation, to stimulate natural circuits of resolution (<xref ref-type="bibr" rid="B39">Chiang and Serhan, 2017</xref>). The objective of this new therapeutic pathway is to administer these analogs in association with classical therapy in order to decrease the doses, thus limiting the secondary effects. A clinical trial has reported for the first time the efficacy of an RvE1 analog in patients with dry eye symptoms (Resolvyx Pharmaceuticals). These encouraging results should be extended to the use of such molecules to treat other inflammatory diseases.</p>
</sec>
<sec id="s6" sec-type="conclusions">
<title>Conclusion</title>
<p>In the investigation of new anti-inflammatory treatments without the secondary effects of traditional therapy, SPMs are promising therapeutic compounds: they are of natural origin and are active at low concentrations (nM) as compared with their precursor (µM) (<xref ref-type="bibr" rid="B5">Ariel and Serhan, 2007</xref>; <xref ref-type="bibr" rid="B10">Bannenberg and Serhan, 2010</xref>). SPMs are detectable in the brain and their level can be modulated by dietary supplementation. They have potent anti-inflammatory and pro-resolutive properties and we confirm the main role of nutrition as an environmental factor that greatly influences the inflammatory response. It is important to determine if inflammatory pathologies are due to unresolved inflammation, attributed to a decrease in n-3 LC-PUFA dietary intake leading to a decrease in SPM levels, to an enzyme or receptor polymorphism, to a de-regulation of SPM receptors or to a decrease in their expression. We should also determine if these mechanisms could be restored by n-3 LC-PUFA or SPM analog administration.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>All authors (CJ, CR, SL) contributed to the writing of the manuscript.</p>
</sec>
<sec id="s8">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abdelmoaty</surname><given-names>S.</given-names></name><name><surname>Wigerblad</surname><given-names>G.</given-names></name><name><surname>Bas</surname><given-names>D. B.</given-names></name><name><surname>Codeluppi</surname><given-names>S.</given-names></name><name><surname>Fernandez-Zafra</surname><given-names>T.</given-names></name><name><surname>El-Awady el</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Spinal actions of lipoxin A4 and 17(R)-resolvin D1 attenuate inflammation-induced mechanical hypersensitivity and spinal TNF release</article-title>. <source/>PLoS One
<volume>8</volume>, <elocation-id>e75543</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0075543</pub-id><pub-id pub-id-type="pmid">24086560</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aid</surname><given-names>S.</given-names></name><name><surname>Vancassel</surname><given-names>S.</given-names></name><name><surname>Poumes-Ballihaut</surname><given-names>C.</given-names></name><name><surname>Chalon</surname><given-names>S.</given-names></name><name><surname>Guesnet</surname><given-names>P.</given-names></name><name><surname>Lavialle</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Effect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat hippocampus</article-title>. <source/>J. Lipid Res.
<volume>44</volume>, <fpage>1545</fpage>–<lpage>1551</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M300079-JLR200</pub-id><pub-id pub-id-type="pmid">12754277</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alashmali</surname><given-names>S. M.</given-names></name><name><surname>Hopperton</surname><given-names>K. E.</given-names></name><name><surname>Bazinet</surname><given-names>R. P.</given-names></name></person-group> (<year>2016</year>). <article-title>Lowering dietary n-6 polyunsaturated fatty acids: interaction with brain arachidonic and docosahexaenoic acids</article-title>. <source/>Curr. Opin. Lipidol.
<volume>27</volume>, <fpage>54</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1097/MOL.0000000000000255</pub-id><pub-id pub-id-type="pmid">26709472</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">Antonietta <person-group person-group-type="author"><name><surname>Ajmone-Cat</surname><given-names>M.</given-names></name><name><surname>Lavinia Salvatori</surname><given-names>M.</given-names></name><name><surname>De Simone</surname><given-names>R.</given-names></name><name><surname>Mancini</surname><given-names>M.</given-names></name><name><surname>Biagioni</surname><given-names>S.</given-names></name><name><surname>Bernardo</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Docosahexaenoic acid modulates inflammatory and antineurogenic functions of activated microglial cells</article-title>. <source/>J. Neurosci. Res.
<volume>90</volume>, <fpage>575</fpage>–<lpage>587</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.22783</pub-id><pub-id pub-id-type="pmid">22057807</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ariel</surname><given-names>A.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2007</year>). <article-title>Resolvins and protectins in the termination program of acute inflammation</article-title>. <source/>Trends Immunol.
<volume>28</volume>, <fpage>176</fpage>–<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2007.02.007</pub-id><pub-id pub-id-type="pmid">17337246</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Ohira</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>Y. P.</given-names></name><name><surname>Elangovan</surname><given-names>S.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2007</year>). <article-title>Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation</article-title>. <source/>J. Immunol.
<volume>178</volume>, <fpage>3912</fpage>–<lpage>3917</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.178.6.3912</pub-id><pub-id pub-id-type="pmid">17339491</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asatryan</surname><given-names>A.</given-names></name><name><surname>Bazan</surname><given-names>N. G.</given-names></name></person-group> (<year>2017</year>). <article-title>Molecular mechanisms of signaling via the docosanoid neuroprotectin D1 for cellular homeostasis and neuroprotection</article-title>. <source/>J. Biol. Chem.
<volume>292</volume>, <fpage>12390</fpage>–<lpage>12397</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.R117.783076</pub-id><pub-id pub-id-type="pmid">28615451</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aursnes</surname><given-names>M.</given-names></name><name><surname>Tungen</surname><given-names>J. E.</given-names></name><name><surname>Vik</surname><given-names>A.</given-names></name><name><surname>Colas</surname><given-names>R.</given-names></name><name><surname>Cheng</surname><given-names>C.-Y. C.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Total synthesis of the lipid mediator PD1n-3 DPA: configurational assignments and anti-inflammatory and pro-resolving actions</article-title>. <source/>J. Nat. Prod.
<volume>77</volume>, <fpage>910</fpage>–<lpage>916</lpage>. <pub-id pub-id-type="doi">10.1021/np4009865</pub-id><pub-id pub-id-type="pmid">24576195</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balvers</surname><given-names>M. G.</given-names></name><name><surname>Verhoeckx</surname><given-names>K. C.</given-names></name><name><surname>Bijlsma</surname><given-names>S.</given-names></name><name><surname>Rubingh</surname><given-names>C. M.</given-names></name><name><surname>Meijerink</surname><given-names>J.</given-names></name><name><surname>Wortelboer</surname><given-names>H. M.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes in mouse plasma and tissues</article-title>. <source/>Metabolomics
<volume>8</volume>, <fpage>1130</fpage>–<lpage>1147</lpage>. <pub-id pub-id-type="doi">10.1007/s11306-012-0421-9</pub-id><pub-id pub-id-type="pmid">23136559</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bannenberg</surname><given-names>G.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2010</year>). <article-title>Specialized pro-resolving lipid mediators in the inflammatory response: an update</article-title>. <source/>Biochim. Biophys. Acta
<volume>1801</volume>, <fpage>1260</fpage>–<lpage>1273</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2010.08.002</pub-id><pub-id pub-id-type="pmid">20708099</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barden</surname><given-names>A. E.</given-names></name><name><surname>Mas</surname><given-names>E.</given-names></name><name><surname>Mori</surname><given-names>T. A.</given-names></name></person-group> (<year>2016</year>). <article-title>n-3 Fatty acid supplementation and proresolving mediators of inflammation</article-title>. <source/>Curr. Opin. Lipidol.
<volume>27</volume>, <fpage>26</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1097/MOL.0000000000000262</pub-id><pub-id pub-id-type="pmid">26655290</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barden</surname><given-names>A.</given-names></name><name><surname>Mas</surname><given-names>E.</given-names></name><name><surname>Croft</surname><given-names>K. D.</given-names></name><name><surname>Phillips</surname><given-names>M.</given-names></name><name><surname>Mori</surname><given-names>T. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation</article-title>. <source/>J. Lipid Res.
<volume>55</volume>, <fpage>2401</fpage>–<lpage>2407</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M045583</pub-id><pub-id pub-id-type="pmid">25187667</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bascoul-Colombo</surname><given-names>C.</given-names></name><name><surname>Guschina</surname><given-names>I. A.</given-names></name><name><surname>Maskrey</surname><given-names>B. H.</given-names></name><name><surname>Good</surname><given-names>M.</given-names></name><name><surname>O’Donnell</surname><given-names>V. B.</given-names></name><name><surname>Harwood</surname><given-names>J. L.</given-names></name></person-group> (<year>2016</year>). <article-title>Dietary DHA supplementation causes selective changes in phospholipids from different brain regions in both wild type mice and the Tg2576 mouse model of Alzheimer’s disease</article-title>. <source/>Biochim. Biophys. Acta
<volume>1861</volume>, <fpage>524</fpage>–<lpage>537</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2016.03.005</pub-id><pub-id pub-id-type="pmid">26968097</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bazan</surname><given-names>N. G.</given-names></name></person-group> (<year>2008</year>). <article-title>Neurotrophins induce neuroprotective signaling in the retinal pigment epithelial cell by activating the synthesis of the anti-inflammatory and anti-apoptotic neuroprotectin D1</article-title>. <source/>Adv. Exp. Med. Biol.
<volume>613</volume>, <fpage>39</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-74904-4_3</pub-id><pub-id pub-id-type="pmid">18188926</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bazan</surname><given-names>N. G.</given-names></name></person-group> (<year>2009</year>). <article-title>Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>81</volume>, <fpage>205</fpage>–<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2009.05.024</pub-id><pub-id pub-id-type="pmid">19520558</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bazan</surname><given-names>N. G.</given-names></name><name><surname>Eady</surname><given-names>T. N.</given-names></name><name><surname>Khoutorova</surname><given-names>L.</given-names></name><name><surname>Atkins</surname><given-names>K. D.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke</article-title>. <source/>Exp. Neurol.
<volume>236</volume>, <fpage>122</fpage>–<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2012.04.007</pub-id><pub-id pub-id-type="pmid">22542947</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bazinet</surname><given-names>R. P.</given-names></name><name><surname>Metherel</surname><given-names>A. H.</given-names></name><name><surname>Chen</surname><given-names>C. T.</given-names></name><name><surname>Raza Shaikh</surname><given-names>S.</given-names></name><name><surname>Nadjar</surname><given-names>A.</given-names></name><name><surname>Joffre</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression</article-title>. <source/>Brain Behav. Immun.
<pub-id pub-id-type="doi">10.1016/j.bbi.2019.07.001</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Birnie</surname><given-names>M.</given-names></name><name><surname>Morrison</surname><given-names>R.</given-names></name><name><surname>Camara</surname><given-names>R.</given-names></name><name><surname>Strauss</surname><given-names>K. I.</given-names></name></person-group> (<year>2013</year>). <article-title>Temporal changes of cytochrome P450 (Cyp) and eicosanoid-related gene expression in the rat brain after traumatic brain injury</article-title>. <source/>BMC Genomics
<volume>14</volume>, <elocation-id>303</elocation-id>. <pub-id pub-id-type="doi">10.1186/1471-2164-14-303</pub-id><pub-id pub-id-type="pmid">23642095</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bisicchia</surname><given-names>E.</given-names></name><name><surname>Sasso</surname><given-names>V.</given-names></name><name><surname>Catanzaro</surname><given-names>G.</given-names></name><name><surname>Leuti</surname><given-names>A.</given-names></name><name><surname>Besharat</surname><given-names>Z. M.</given-names></name><name><surname>Chiacchiarini</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Resolvin D1 halts remote neuroinflammation and improves functional recovery after focal brain damage via ALX/FPR2 receptor-regulated microRNAs</article-title>. <source/>Mol. Neurobiol.
<volume>55</volume>, <fpage>6894</fpage>–<lpage>6905</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-018-0889-z</pub-id><pub-id pub-id-type="pmid">29357041</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blais</surname><given-names>V.</given-names></name><name><surname>Rivest</surname><given-names>S.</given-names></name></person-group> (<year>2003</year>). <article-title>[Role of the innate immune response in the brain]</article-title>. <source/>Med. Sci. (Paris)
<volume>19</volume>, <fpage>981</fpage>–<lpage>987</lpage>. <pub-id pub-id-type="doi">10.1051/medsci/20031910981</pub-id><pub-id pub-id-type="pmid">14613011</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boudrault</surname><given-names>C.</given-names></name><name><surname>Bazinet</surname><given-names>R. P.</given-names></name><name><surname>Kang</surname><given-names>J. X.</given-names></name><name><surname>Ma</surname><given-names>D. W.</given-names></name></person-group> (<year>2010</year>). <article-title>Cyclooxygenase-2 and n-6 PUFA are lower and DHA is higher in the cortex of fat-1 mice</article-title>. <source/>Neurochem. Int.
<volume>56</volume>, <fpage>585</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2009.12.022</pub-id><pub-id pub-id-type="pmid">20064570</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bourre</surname><given-names>J. M.</given-names></name><name><surname>Pascal</surname><given-names>G.</given-names></name><name><surname>Durand</surname><given-names>G.</given-names></name><name><surname>Masson</surname><given-names>M.</given-names></name><name><surname>Dumont</surname><given-names>O.</given-names></name><name><surname>Piciotti</surname><given-names>M.</given-names></name></person-group> (<year>1984</year>). <article-title>Alterations in the fatty acid composition of rat brain cells (neurons, astrocytes, and oligodendrocytes) and of subcellular fractions (myelin and synaptosomes) induced by a diet devoid of n-3 fatty acids</article-title>. <source/>J. Neurochem.
<volume>43</volume>, <fpage>342</fpage>–<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.1984.tb00906.x</pub-id><pub-id pub-id-type="pmid">6736955</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bove</surname><given-names>M.</given-names></name><name><surname>Mhillaj</surname><given-names>E.</given-names></name><name><surname>Tucci</surname><given-names>P.</given-names></name><name><surname>Giardino</surname><given-names>I.</given-names></name><name><surname>Schiavone</surname><given-names>S.</given-names></name><name><surname>Morgese</surname><given-names>M. G.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Effects of n-3 PUFA enriched and n-3 PUFA deficient diets in naïve and Aβ-treated female rats</article-title>. <source/>Biochem. Pharmacol.
<volume>155</volume>, <fpage>326</fpage>–<lpage>335</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2018.07.017</pub-id><pub-id pub-id-type="pmid">30028991</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bowen</surname><given-names>R. A.</given-names></name><name><surname>Clandinin</surname><given-names>M. T.</given-names></name></person-group> (<year>2005</year>). <article-title>Maternal dietary 22: 6n-3 is more effective than 18: 3n-3 in increasing the 22: 6n-3 content in phospholipids of glial cells from neonatal rat brain</article-title>. <source/>Br. J. Nutr.
<volume>93</volume>, <fpage>601</fpage>–<lpage>611</lpage>. <pub-id pub-id-type="doi">10.1079/BJN20041390</pub-id><pub-id pub-id-type="pmid">15975158</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Broadhurst</surname><given-names>C. L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Crawford</surname><given-names>M. A.</given-names></name><name><surname>Cunnane</surname><given-names>S. C.</given-names></name><name><surname>Parkington</surname><given-names>J. E.</given-names></name><name><surname>Schmidt</surname><given-names>W. F.</given-names></name></person-group> (<year>2002</year>). <article-title>Brain-specific lipids from marine, lacustrine, or terrestrial food resources: potential impact on early African Homo sapiens</article-title>. <source/>Comp. Biochem. Physiol. B Biochem. Mol. Biol.
<volume>131</volume>, <fpage>653</fpage>–<lpage>673</lpage>. <pub-id pub-id-type="doi">10.1016/S1096-4959(02)00002-7</pub-id><pub-id pub-id-type="pmid">11923081</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bystrom</surname><given-names>J.</given-names></name><name><surname>Wray</surname><given-names>J. A.</given-names></name><name><surname>Sugden</surname><given-names>M. C.</given-names></name><name><surname>Holness</surname><given-names>M. J.</given-names></name><name><surname>Swales</surname><given-names>K. E.</given-names></name><name><surname>Warner</surname><given-names>T. D.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Endogenous epoxygenases are modulators of monocyte/macrophage activity</article-title>. <source/>PLoS One
<volume>6</volume>, <elocation-id>e26591</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0026591</pub-id><pub-id pub-id-type="pmid">22028915</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cagnin</surname><given-names>A.</given-names></name><name><surname>Brooks</surname><given-names>D. J.</given-names></name><name><surname>Kennedy</surname><given-names>A. M.</given-names></name><name><surname>Gunn</surname><given-names>R. N.</given-names></name><name><surname>Myers</surname><given-names>R.</given-names></name><name><surname>Turkheimer</surname><given-names>F. E.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>In-vivo measurement of activated microglia in dementia</article-title>. <source/>Lancet
<volume>358</volume>, <fpage>461</fpage>–<lpage>467</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(01)05625-2</pub-id><pub-id pub-id-type="pmid">11513911</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calandria</surname><given-names>J. M.</given-names></name><name><surname>Bazan</surname><given-names>N. G.</given-names></name></person-group> (<year>2010</year>). <article-title>Neuroprotectin D1 modulates the induction of pro-inflammatory signaling and promotes retinal pigment epithelial cell survival during oxidative stress</article-title>. <source/>Adv. Exp. Med. Biol.
<volume>664</volume>, <fpage>663</fpage>–<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4419-1399-9_76</pub-id><pub-id pub-id-type="pmid">20238071</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calder</surname><given-names>P. C.</given-names></name></person-group> (<year>2005</year>). <article-title>Polyunsaturated fatty acids and inflammation</article-title>. <source/>Biochem. Soc. Trans.
<volume>33</volume>, <fpage>423</fpage>–<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1042/BST0330423</pub-id><pub-id pub-id-type="pmid">15787620</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calder</surname><given-names>P. C.</given-names></name></person-group> (<year>2016</year>). <article-title>Docosahexaenoic Acid</article-title>. <source/>Ann. Nutr. Metab.
<volume>69</volume>
<issue>Suppl 1</issue>, <fpage>7</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1159/000448262</pub-id><pub-id pub-id-type="pmid">27842299</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calder</surname><given-names>P. C.</given-names></name><name><surname>Bosco</surname><given-names>N.</given-names></name><name><surname>Bourdet-Sicard</surname><given-names>R.</given-names></name><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Delzenne</surname><given-names>N.</given-names></name><name><surname>Doré</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition</article-title>. <source/>Ageing Res. Rev.
<volume>40</volume>, <fpage>95</fpage>–<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2017.09.001</pub-id><pub-id pub-id-type="pmid">28899766</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carrie</surname><given-names>I.</given-names></name><name><surname>Clement</surname><given-names>M.</given-names></name><name><surname>de Javel</surname><given-names>D.</given-names></name><name><surname>Frances</surname><given-names>H.</given-names></name><name><surname>Bourre</surname><given-names>J. M.</given-names></name></person-group> (<year>2000</year>). <article-title>Specific phospholipid fatty acid composition of brain regions in mice. Effects of n-3 polyunsaturated fatty acid deficiency and phospholipid supplementation</article-title>. <source/>J. Lipid Res.
<volume>41</volume>, <fpage>465</fpage>–<lpage>472</lpage>.<pub-id pub-id-type="pmid">10706594</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Celis-Morales</surname><given-names>C.</given-names></name><name><surname>Livingstone</surname><given-names>K. M.</given-names></name><name><surname>Affleck</surname><given-names>A.</given-names></name><name><surname>Navas-Carretero</surname><given-names>S.</given-names></name><name><surname>San-Cristobal</surname><given-names>R.</given-names></name><name><surname>Martinez</surname><given-names>J. A.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Correlates of overall and central obesity in adults from seven European countries: findings from the Food4Me Study</article-title>. <source/>Eur. J. Clin. Nutr.
<volume>72</volume>, <fpage>207</fpage>–<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1038/s41430-017-0004-y</pub-id><pub-id pub-id-type="pmid">29242527</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chalon</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Omega-3 fatty acids and monoamine neurotransmission</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>75</volume>, <fpage>259</fpage>–<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2006.07.005</pub-id><pub-id pub-id-type="pmid">16963244</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>C. T.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Bazinet</surname><given-names>R. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Rapid de-esterification and loss of eicosapentaenoic acid from rat brain phospholipids: an intracerebroventricular study</article-title>. <source/>J. Neurochem.
<volume>116</volume>, <fpage>363</fpage>–<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.07116.x</pub-id><pub-id pub-id-type="pmid">21091476</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Pu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Leak</surname><given-names>R. K.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>n-3 PUFA supplementation benefits microglial responses to myelin pathology</article-title>. <source/>Sci. Rep.
<volume>4</volume>, <elocation-id>7458</elocation-id>. <pub-id pub-id-type="doi">10.1038/srep07458</pub-id><pub-id pub-id-type="pmid">25500548</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Xie</surname><given-names>B.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-kappaB pathway following experimental traumatic brain injury</article-title>. <source/>J. Neuroinflamm.
<volume>14</volume>, <fpage>143</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-017-0917-3</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Fredman</surname><given-names>G.</given-names></name><name><surname>Backhed</surname><given-names>F.</given-names></name><name><surname>Oh</surname><given-names>S. F.</given-names></name><name><surname>Vickery</surname><given-names>T.</given-names></name><name><surname>Schmidt</surname><given-names>B. A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Infection regulates pro-resolving mediators that lower antibiotic requirements</article-title>. <source/>Nature
<volume>484</volume>, <fpage>524</fpage>–<lpage>528</lpage>. <pub-id pub-id-type="doi">10.1038/nature11042</pub-id><pub-id pub-id-type="pmid">22538616</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2017</year>). <article-title>Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors</article-title>. <source/>Mol. Aspects Med.
<volume>58</volume>, <fpage>114</fpage>–<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2017.03.005</pub-id><pub-id pub-id-type="pmid">28336292</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chinnici</surname><given-names>C. M.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Pratico</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old</article-title>. <source/>Neurobiol. Aging
<volume>28</volume>, <fpage>1457</fpage>–<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.06.007</pub-id><pub-id pub-id-type="pmid">16930777</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>H. P.</given-names></name><name><surname>Nakamura</surname><given-names>M. T.</given-names></name><name><surname>Clarke</surname><given-names>S. D.</given-names></name></person-group> (<year>1999</year>). <article-title>Cloning, expression, and nutritional regulation of the mammalian Delta-6 desaturase</article-title>. <source/>J. Biol. Chem.
<volume>274</volume>, <fpage>471</fpage>–<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.1.471</pub-id><pub-id pub-id-type="pmid">9867867</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chouinard-Watkins</surname><given-names>R.</given-names></name><name><surname>Bazinet</surname><given-names>R. P.</given-names></name></person-group> (<year>2018</year>). <article-title>ACSL6 is critical for maintaining brain DHA levels</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>115</volume>, <fpage>12343</fpage>–<lpage>12345</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1817557115</pub-id><pub-id pub-id-type="pmid">30446610</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chung</surname><given-names>W. L.</given-names></name><name><surname>Chen</surname><given-names>J. J.</given-names></name><name><surname>Su</surname><given-names>H. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Fish oil supplementation of control and (n-3) fatty acid-deficient male rats enhances reference and working memory performance and increases brain regional docosahexaenoic acid levels</article-title>. <source/>J. Nutr.
<volume>138</volume>, <fpage>1165</fpage>–<lpage>1171</lpage>. <pub-id pub-id-type="doi">10.1093/jn/138.6.1165</pub-id><pub-id pub-id-type="pmid">18492851</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clària</surname><given-names>J.</given-names></name><name><surname>López-Vicario</surname><given-names>C.</given-names></name><name><surname>Rius</surname><given-names>B.</given-names></name><name><surname>Titos</surname><given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>Pro-resolving actions of SPM in adipose tissue biology</article-title>. <source/>Mol. Aspects Med.
<volume>58</volume>, <fpage>83</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2017.03.004</pub-id><pub-id pub-id-type="pmid">28341541</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Colas</surname><given-names>R. A.</given-names></name><name><surname>Shinohara</surname><given-names>M.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2014</year>). <article-title>Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue</article-title>. <source/>Am. J. Physiol. Cell. Physiol.
<volume>307</volume>, <fpage>C39</fpage>–<lpage>C54</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00024.2014</pub-id><pub-id pub-id-type="pmid">24696140</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cooray</surname><given-names>S. N.</given-names></name><name><surname>Gobbetti</surname><given-names>T.</given-names></name><name><surname>Montero-Melendez</surname><given-names>T.</given-names></name><name><surname>McArthur</surname><given-names>S.</given-names></name><name><surname>Thompson</surname><given-names>D.</given-names></name><name><surname>Clark</surname><given-names>A. J.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>110</volume>, <fpage>18232</fpage>–<lpage>18237</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1308253110</pub-id><pub-id pub-id-type="pmid">24108355</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Corsi</surname><given-names>L.</given-names></name><name><surname>Dongmo</surname><given-names>B. M.</given-names></name><name><surname>Avallone</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>Supplementation of omega 3 fatty acids improves oxidative stress in activated BV2 microglial cell line</article-title>. <source/>Int. J. Food Sci. Nutr.
<volume>66</volume>, <fpage>293</fpage>–<lpage>299</lpage>. <pub-id pub-id-type="doi">10.3109/09637486.2014.986073</pub-id><pub-id pub-id-type="pmid">25582176</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crawford</surname><given-names>M. A.</given-names></name><name><surname>Bloom</surname><given-names>M.</given-names></name><name><surname>Broadhurst</surname><given-names>C. L.</given-names></name><name><surname>Schmidt</surname><given-names>W. F.</given-names></name><name><surname>Cunnane</surname><given-names>S. C.</given-names></name><name><surname>Galli</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>1999</year>). <article-title>Evidence for the unique function of docosahexaenoic acid during the evolution of the modern hominid brain</article-title>. <source/>Lipids
<volume>34</volume>
<issue>Suppl</issue>, <fpage>S39</fpage>–<lpage>S47</lpage>. <pub-id pub-id-type="doi">10.1007/BF02562227</pub-id><pub-id pub-id-type="pmid">10419087</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>C.</given-names></name><name><surname>Sanderson</surname><given-names>D. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Malaise in the water maze: untangling the effects of LPS and IL-1beta on learning and memory</article-title>. <source/>Brain Behav. Immun.
<volume>22</volume>, <fpage>1117</fpage>–<lpage>1127</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2008.05.007</pub-id><pub-id pub-id-type="pmid">18640811</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Czapski</surname><given-names>G. A.</given-names></name><name><surname>Gajkowska</surname><given-names>B.</given-names></name><name><surname>Strosznajder</surname><given-names>J. B.</given-names></name></person-group> (<year>2010</year>). <article-title>Systemic administration of lipopolysaccharide induces molecular and morphological alterations in the hippocampus</article-title>. <source/>Brain Res.
<volume>1356</volume>, <fpage>85</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2010.07.096</pub-id><pub-id pub-id-type="pmid">20696148</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2012</year>). <article-title>Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators</article-title>. <source/>Blood
<volume>120</volume>, <fpage>e60</fpage>–<lpage>e72</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2012-04-423525</pub-id><pub-id pub-id-type="pmid">22904297</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Winkler</surname><given-names>J. W.</given-names></name><name><surname>Colas</surname><given-names>R. A.</given-names></name><name><surname>Arnardottir</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>C. Y.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2013</year>a). <article-title>Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents</article-title>. <source/>Chem. Biol.
<volume>20</volume>, <fpage>188</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2012.11.010</pub-id><pub-id pub-id-type="pmid">23438748</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Vlasenko</surname><given-names>N. A.</given-names></name><name><surname>Deng</surname><given-names>B.</given-names></name><name><surname>Haeggstrom</surname><given-names>J. Z.</given-names></name><name><surname>Petasis</surname><given-names>N. A.</given-names></name><etal></etal></person-group> (<year>2013</year>b). <article-title>The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype</article-title>. <source/>FASEB J.
<volume>27</volume>, <fpage>2573</fpage>–<lpage>2583</lpage>. <pub-id pub-id-type="doi">10.1096/fj.13-227728</pub-id><pub-id pub-id-type="pmid">23504711</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davidson</surname><given-names>J.</given-names></name><name><surname>Abul</surname><given-names>H. T.</given-names></name><name><surname>Milton</surname><given-names>A. S.</given-names></name><name><surname>Rotondo</surname><given-names>D.</given-names></name></person-group> (<year>2001</year>). <article-title>Cytokines and cytokine inducers stimulate prostaglandin E2 entry into the brain</article-title>. <source/>Pflugers Arch.
<volume>442</volume>, <fpage>526</fpage>–<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1007/s004240100572</pub-id><pub-id pub-id-type="pmid">11510884</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Smedt-Peyrusse</surname><given-names>V.</given-names></name><name><surname>Sargueil</surname><given-names>F.</given-names></name><name><surname>Moranis</surname><given-names>A.</given-names></name><name><surname>Harizi</surname><given-names>H.</given-names></name><name><surname>Mongrand</surname><given-names>S.</given-names></name><name><surname>Layé</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Docosahexaenoic acid prevents lipopolysaccharide-induced cytokine production in microglial cells by inhibiting lipopolysaccharide receptor presentation but not its membrane subdomain localization</article-title>. <source/>J. Neurochem.
<volume>105</volume>, <fpage>296</fpage>–<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.05129.x</pub-id><pub-id pub-id-type="pmid">18021297</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Theije</surname><given-names>C. G.</given-names></name><name><surname>van den Elsen</surname><given-names>L. W.</given-names></name><name><surname>Willemsen</surname><given-names>L. E.</given-names></name><name><surname>Milosevic</surname><given-names>V.</given-names></name><name><surname>Korte-Bouws</surname><given-names>G. A.</given-names></name><name><surname>Lopes da Silva</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Dietary long chain n-3 polyunsaturated fatty acids prevent impaired social behaviour and normalize brain dopamine levels in food allergic mice</article-title>. <source/>Neuropharmacology
<volume>90</volume>, <fpage>15</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.11.001</pub-id><pub-id pub-id-type="pmid">25445491</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dehkordi</surname><given-names>N. G.</given-names></name><name><surname>Noorbakhshnia</surname><given-names>M.</given-names></name><name><surname>Ghaedi</surname><given-names>K.</given-names></name><name><surname>Esmaeili</surname><given-names>A.</given-names></name><name><surname>Dabaghi</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Omega-3 fatty acids prevent LPS-induced passive avoidance learning and memory and CaMKII-alpha gene expression impairments in hippocampus of rat</article-title>. <source/>Pharmacol. Rep.
<volume>67</volume>, <fpage>370</fpage>–<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharep.2014.10.014</pub-id><pub-id pub-id-type="pmid">25712666</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Delpech</surname><given-names>J.-C.</given-names></name><name><surname>Madore</surname><given-names>C.</given-names></name><name><surname>Joffre</surname><given-names>C.</given-names></name><name><surname>Aubert</surname><given-names>A.</given-names></name><name><surname>Kang</surname><given-names>J. X.</given-names></name><name><surname>Nadjar</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>a). <article-title>Transgenic increase in n-3/n-6 fatty acid ratio protects against cognitive deficits induced by an immune challenge through decrease of neuroinflammation</article-title>. <source/>Neuropsychopharmacology
<volume>40</volume>, <fpage>525</fpage>–<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2014.196</pub-id><pub-id pub-id-type="pmid">25228141</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Delpech</surname><given-names>J.-C.</given-names></name><name><surname>Thomazeau</surname><given-names>A.</given-names></name><name><surname>Madore</surname><given-names>C.</given-names></name><name><surname>Bosch-Bouju</surname><given-names>C.</given-names></name><name><surname>Larrieu</surname><given-names>T.</given-names></name><name><surname>Lacabanne</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2015</year>b). <article-title>Dietary n-3 PUFAs deficiency increases vulnerability to inflammation—induced spatial memory impairment</article-title>. <source/>Neuropsychopharmacology
<volume>40</volume>, <fpage>2774</fpage>–<lpage>2787</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2015.127</pub-id><pub-id pub-id-type="pmid">25948102</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Destaillats</surname><given-names>F.</given-names></name><name><surname>Joffre</surname><given-names>C.</given-names></name><name><surname>Acar</surname><given-names>N.</given-names></name><name><surname>Joffre</surname><given-names>F.</given-names></name><name><surname>Bezelgues</surname><given-names>J. B.</given-names></name><name><surname>Pasquis</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Differential effect of maternal diet supplementation with alpha-Linolenic adcid or n-3 long-chain polyunsaturated fatty acids on glial cell phosphatidylethanolamine and phosphatidylserine fatty acid profile in neonate rat brains</article-title>. <source/>Nutr. Metab. (Lond.)
<volume>7</volume>, <elocation-id>2</elocation-id>. <pub-id pub-id-type="doi">10.1186/1743-7075-7-2</pub-id><pub-id pub-id-type="pmid">20148111</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deyama</surname><given-names>S.</given-names></name><name><surname>Ishikawa</surname><given-names>Y.</given-names></name><name><surname>Yoshikawa</surname><given-names>K.</given-names></name><name><surname>Shimoda</surname><given-names>K.</given-names></name><name><surname>Ide</surname><given-names>S.</given-names></name><name><surname>Satoh</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Resolvin D1 and D2 reverse lipopolysaccharide-induced depression-like behaviors through the mTORC1 signaling pathway</article-title>. <source/>Int. J. Neuropsychopharmacol.
<volume>20</volume>, <fpage>575</fpage>–<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1093/ijnp/pyx023</pub-id><pub-id pub-id-type="pmid">28419244</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deyama</surname><given-names>S.</given-names></name><name><surname>Shimoda</surname><given-names>K.</given-names></name><name><surname>Ikeda</surname><given-names>H.</given-names></name><name><surname>Fukuda</surname><given-names>H.</given-names></name><name><surname>Shuto</surname><given-names>S.</given-names></name><name><surname>Minami</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>a). <article-title>Resolvin E3 attenuates lipopolysaccharide-induced depression-like behavior in mice</article-title>. <source/>J. Pharmacol. Sci.
<volume>138</volume>, <fpage>86</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.jphs.2018.09.006</pub-id><pub-id pub-id-type="pmid">30293959</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deyama</surname><given-names>S.</given-names></name><name><surname>Shimoda</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Ishikawa</surname><given-names>Y.</given-names></name><name><surname>Ishimura</surname><given-names>K.</given-names></name><name><surname>Fukuda</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2018</year>b). <article-title>Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23</article-title>. <source/>Psychopharmacol. (Berl.)
<volume>235</volume>, <fpage>329</fpage>–<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-017-4774-7</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Meco</surname><given-names>A.</given-names></name><name><surname>Lauretti</surname><given-names>E.</given-names></name><name><surname>Vagnozzi</surname><given-names>A. N.</given-names></name><name><surname>Pratico</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer’s disease mice</article-title>. <source/>Neurobiol. Aging
<volume>35</volume>, <fpage>2458</fpage>–<lpage>2464</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.05.016</pub-id><pub-id pub-id-type="pmid">24973121</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dieter</surname><given-names>P.</given-names></name><name><surname>Scheibe</surname><given-names>R.</given-names></name><name><surname>Kamionka</surname><given-names>S.</given-names></name><name><surname>Kolada</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>LPS-induced synthesis and release of PGE2 in liver macrophages: regulation by CPLA2, COX-1, COX-2, and PGE2 synthase</article-title>. <source/>Adv. Exp. Med. Biol.
<volume>507</volume>, <fpage>457</fpage>–<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4615-0193-0_71</pub-id><pub-id pub-id-type="pmid">12664626</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Kalueff</surname><given-names>A. V.</given-names></name><name><surname>Song</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>Dietary eicosapentaenoic acid normalizes hippocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates glial activation and regulates BDNF function in a rodent model of neuroinflammation induced by central interleukin-1beta administration</article-title>. <source/>Eur. J. Nutr.
<pub-id pub-id-type="doi">10.1007/s00394-017-1462-7</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doyle</surname><given-names>R.</given-names></name><name><surname>Sadlier</surname><given-names>D. M.</given-names></name><name><surname>Godson</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>Pro-resolving lipid mediators: agents of anti-ageing</article-title>? <source/>Semin. Immunol.
<volume>40</volume>, <fpage>36</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.smim.2018.09.002</pub-id><pub-id pub-id-type="pmid">30293857</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dyerberg</surname><given-names>J.</given-names></name><name><surname>Bang</surname><given-names>H. O.</given-names></name></person-group> (<year>1979</year>). <article-title>Haemostatic function and platelet polyunsaturated fatty acids in Eskimos</article-title>. <source/>Lancet
<volume>2</volume>, <fpage>433</fpage>–<lpage>435</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(79)91490-9</pub-id><pub-id pub-id-type="pmid">89498</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Engstrom</surname><given-names>L.</given-names></name><name><surname>Ruud</surname><given-names>J.</given-names></name><name><surname>Eskilsson</surname><given-names>A.</given-names></name><name><surname>Larsson</surname><given-names>A.</given-names></name><name><surname>Mackerlova</surname><given-names>L.</given-names></name><name><surname>Kugelberg</surname><given-names>U.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Lipopolysaccharide-induced fever depends on prostaglandin E2 production specifically in brain endothelial cells</article-title>. <source/>Endocrinology
<volume>153</volume>, <fpage>4849</fpage>–<lpage>4861</lpage>. <pub-id pub-id-type="doi">10.1210/en.2012-1375</pub-id><pub-id pub-id-type="pmid">22872578</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Famenini</surname><given-names>S.</given-names></name><name><surname>Rigali</surname><given-names>E. A.</given-names></name><name><surname>Olivera-Perez</surname><given-names>H. M.</given-names></name><name><surname>Dang</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>M. T.</given-names></name><name><surname>Halder</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on omega-3 supplementation</article-title>. <source/>FASEB J.
<volume>31</volume>, <fpage>148</fpage>–<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201600677RR</pub-id><pub-id pub-id-type="pmid">27677546</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farias</surname><given-names>S. E.</given-names></name><name><surname>Basselin</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>Heidenreich</surname><given-names>K. A.</given-names></name><name><surname>Rapoport</surname><given-names>S. I.</given-names></name><name><surname>Murphy</surname><given-names>R. C.</given-names></name></person-group> (<year>2008</year>). <article-title>Formation of eicosanoids, E2/D2 isoprostanes, and docosanoids following decapitation-induced ischemia, measured in high-energy-microwaved rat brain</article-title>. <source/>J. Lipid Res.
<volume>49</volume>, <fpage>1990</fpage>–<lpage>2000</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M800200-JLR200</pub-id><pub-id pub-id-type="pmid">18503030</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farooqui</surname><given-names>A. A.</given-names></name><name><surname>Horrocks</surname><given-names>L. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly</article-title>. <source/>Neuroscientist
<volume>12</volume>, <fpage>245</fpage>–<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1177/1073858405285923</pub-id><pub-id pub-id-type="pmid">16684969</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>R. F.</given-names></name><name><surname>Kim</surname><given-names>S. Q.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Foguth</surname><given-names>R. M.</given-names></name><name><surname>Weera</surname><given-names>M. M.</given-names></name><name><surname>Counihan</surname><given-names>J. L.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Acyl-CoA synthetase 6 enriches the neuroprotective omega-3 fatty acid DHA in the brain</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>115</volume>, <fpage>12525</fpage>–<lpage>12530</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1807958115</pub-id><pub-id pub-id-type="pmid">30401738</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fleming</surname><given-names>I.</given-names></name></person-group> (<year>2011</year>). <article-title>Cytochrome P450-dependent eicosanoid production and crosstalk</article-title>. <source/>Curr. Opin. Lipidol.
<volume>22</volume>, <fpage>403</fpage>–<lpage>409</lpage>. <pub-id pub-id-type="doi">10.1097/MOL.0b013e32834a9790</pub-id><pub-id pub-id-type="pmid">21825980</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fourrier</surname><given-names>C.</given-names></name><name><surname>Remus-Borel</surname><given-names>J.</given-names></name><name><surname>Greenhalgh</surname><given-names>A. D.</given-names></name><name><surname>Guichardant</surname><given-names>M.</given-names></name><name><surname>Bernoud-Hubac</surname><given-names>N.</given-names></name><name><surname>Lagarde</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Docosahexaenoic acid-containing choline phospholipid modulates LPS-induced neuroinflammation in vivo and in microglia in vitro</article-title>. <source/>J. Neuroinflamm.
<volume>14</volume>, <fpage>170</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-017-0939-x</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Francos-Quijorna</surname><given-names>I.</given-names></name><name><surname>Santos-Nogueira</surname><given-names>E.</given-names></name><name><surname>Gronert</surname><given-names>K.</given-names></name><name><surname>Sullivan</surname><given-names>A. B.</given-names></name><name><surname>Kopp</surname><given-names>M. A.</given-names></name><name><surname>Brommer</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Maresin 1 promotes inflammatory resolution, neuroprotection, and functional neurological recovery after spinal cord injury</article-title>. <source/>J. Neurosci.
<volume>37</volume>, <fpage>11731</fpage>–<lpage>11743</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1395-17.2017</pub-id><pub-id pub-id-type="pmid">29109234</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fredman</surname><given-names>G.</given-names></name><name><surname>Sadhu</surname><given-names>S.</given-names></name><name><surname>Rymut</surname><given-names>N.</given-names></name></person-group> (<year>2017</year>). <article-title>Fine-tuning inflammation-resolution programs: focus on atherosclerosis</article-title>. <source/>Curr. Opin. Clin. Nutr. Metab. Care
<volume>20</volume>, <fpage>117</fpage>–<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1097/MCO.0000000000000351</pub-id><pub-id pub-id-type="pmid">27984234</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fredman</surname><given-names>G.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2011</year>). <article-title>Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution</article-title>. <source/>Biochem. J.
<volume>437</volume>, <fpage>185</fpage>–<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20110327</pub-id><pub-id pub-id-type="pmid">21711247</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Freund-Levi</surname><given-names>Y.</given-names></name><name><surname>Eriksdotter-Jonhagen</surname><given-names>M.</given-names></name><name><surname>Cederholm</surname><given-names>T.</given-names></name><name><surname>Basun</surname><given-names>H.</given-names></name><name><surname>Faxen-Irving</surname><given-names>G.</given-names></name><name><surname>Garlind</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial</article-title>. <source/>Arch. Neurol.
<volume>63</volume>, <fpage>1402</fpage>–<lpage>1408</lpage>. <pub-id pub-id-type="doi">10.1001/archneur.63.10.1402</pub-id><pub-id pub-id-type="pmid">17030655</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Furuyashiki</surname><given-names>T.</given-names></name><name><surname>Akiyama</surname><given-names>S.</given-names></name><name><surname>Kitaoka</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Roles of multiple lipid mediators in stress and depression</article-title>. <source/>Int. Immunol.
<fpage>1781</fpage>–<lpage>1791</lpage>. <pub-id pub-id-type="doi">10.1093/intimm/dxz023</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gabbs</surname><given-names>M.</given-names></name><name><surname>Leng</surname><given-names>S.</given-names></name><name><surname>Devassy</surname><given-names>J. G.</given-names></name><name><surname>Monirujjaman</surname><given-names>M.</given-names></name><name><surname>Aukema</surname><given-names>H. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Advances in our understanding of oxylipins derived from dietary PUFAs</article-title>. <source/>Adv. Nutr.
<volume>6</volume>, <fpage>513</fpage>–<lpage>540</lpage>. <pub-id pub-id-type="doi">10.3945/an.114.007732</pub-id><pub-id pub-id-type="pmid">26374175</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>K.</given-names></name><name><surname>Bernier</surname><given-names>J.</given-names></name><name><surname>Godbout</surname><given-names>R.</given-names></name><name><surname>Rousseau</surname><given-names>G.</given-names></name></person-group> (<year>2014</year>). <article-title>Resolvin D1, a metabolite of omega-3 polyunsaturated fatty acid, decreases post-myocardial infarct depression</article-title>. <source/>Mar. Drugs
<volume>12</volume>, <fpage>5396</fpage>–<lpage>5407</lpage>. <pub-id pub-id-type="doi">10.3390/md12115396</pub-id><pub-id pub-id-type="pmid">25402828</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilroy</surname><given-names>D. W.</given-names></name><name><surname>Edin</surname><given-names>M. L.</given-names></name><name><surname>De Maeyer</surname><given-names>R. P.</given-names></name><name><surname>Bystrom</surname><given-names>J.</given-names></name><name><surname>Newson</surname><given-names>J.</given-names></name><name><surname>Lih</surname><given-names>F. B.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>CYP450-derived oxylipins mediate inflammatory resolution</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>113</volume>, <fpage>E3240</fpage>–<lpage>E3249</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1521453113</pub-id><pub-id pub-id-type="pmid">27226306</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Graham</surname><given-names>K. L.</given-names></name><name><surname>Zabel</surname><given-names>B. A.</given-names></name><name><surname>Loghavi</surname><given-names>S.</given-names></name><name><surname>Zuniga</surname><given-names>L. A.</given-names></name><name><surname>Ho</surname><given-names>P. P.</given-names></name><name><surname>Sobel</surname><given-names>R. A.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease</article-title>. <source/>J. Immunol.
<volume>183</volume>, <fpage>6717</fpage>–<lpage>6723</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0803435</pub-id><pub-id pub-id-type="pmid">19864606</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griffin</surname><given-names>W. S.</given-names></name><name><surname>Stanley</surname><given-names>L. C.</given-names></name><name><surname>Ling</surname><given-names>C.</given-names></name><name><surname>White</surname><given-names>L.</given-names></name><name><surname>MacLeod</surname><given-names>V.</given-names></name><name><surname>Perrot</surname><given-names>L. J.</given-names></name><etal></etal></person-group> (<year>1989</year>). <article-title>Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>86</volume>, <fpage>7611</fpage>–<lpage>7615</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.86.19.7611</pub-id><pub-id pub-id-type="pmid">2529544</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Weng</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Cui</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Chronic mild restraint stress rats decreased CMKLR1 expression in distinct brain region</article-title>. <source/>Neurosci. Lett.
<volume>524</volume>, <fpage>25</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2012.06.075</pub-id><pub-id pub-id-type="pmid">22796467</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>Z. N.</given-names></name><name><surname>Ou</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Lipoxin A4 reduces inflammation through formyl peptide receptor 2/p38 MAPK signaling pathway in subarachnoid hemorrhage rats</article-title>. <source/>Stroke
<volume>47</volume>, <fpage>490</fpage>–<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.115.011223</pub-id><pub-id pub-id-type="pmid">26732571</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halade</surname><given-names>G. V.</given-names></name><name><surname>Black</surname><given-names>L. M.</given-names></name><name><surname>Verma</surname><given-names>M. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Paradigm shift — metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery</article-title>. <source/>Biotechnol. Adv.
<volume>36</volume>, <fpage>935</fpage>– <lpage>953</lpage>. <pub-id pub-id-type="doi">10.1016/j.biotechadv.2018.02.014</pub-id><pub-id pub-id-type="pmid">29499340</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hanisch</surname><given-names>U. K.</given-names></name><name><surname>Kettenmann</surname><given-names>H.</given-names></name></person-group> (<year>2007</year>). <article-title>Microglia: active sensor and versatile effector cells in the normal and pathologic brain</article-title>. <source/>Nat. Neurosci.
<volume>10</volume>, <fpage>1387</fpage>–<lpage>1394</lpage>. <pub-id pub-id-type="doi">10.1038/nn1997</pub-id><pub-id pub-id-type="pmid">17965659</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harrison</surname><given-names>J. L.</given-names></name><name><surname>Rowe</surname><given-names>R. K.</given-names></name><name><surname>Ellis</surname><given-names>T. W.</given-names></name><name><surname>Yee</surname><given-names>N. S.</given-names></name><name><surname>O’Hara</surname><given-names>B. F.</given-names></name><name><surname>Adelson</surname><given-names>P. D.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse</article-title>. <source/>Brain Behav. Immun.
<volume>47</volume>, <fpage>131</fpage>–<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.01.001</pub-id><pub-id pub-id-type="pmid">25585137</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M.</given-names></name><name><surname>Katakura</surname><given-names>M.</given-names></name><name><surname>Tanabe</surname><given-names>Y.</given-names></name><name><surname>Al Mamun</surname><given-names>A.</given-names></name><name><surname>Inoue</surname><given-names>T.</given-names></name><name><surname>Hossain</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>n-3 fatty acids effectively improve the reference memory-related learning ability associated with increased brain docosahexaenoic acid-derived docosanoids in aged rats</article-title>. <source/>Biochim. Biophys. Acta
<volume>1851</volume>, <fpage>203</fpage>–<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2014.10.009</pub-id><pub-id pub-id-type="pmid">25450447</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hecker</surname><given-names>M.</given-names></name><name><surname>Sommer</surname><given-names>N.</given-names></name><name><surname>Foch</surname><given-names>S.</given-names></name><name><surname>Hecker</surname><given-names>A.</given-names></name><name><surname>Hackstein</surname><given-names>H.</given-names></name><name><surname>Witzenrath</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Resolvin E1 and its precursor 18R-HEPE restore mitochondrial function in inflammation</article-title>. <source/>Biochim. Biophys. Acta Mol. Cell. Biol. Lipids
<volume>1863</volume>, <fpage>1016</fpage>–<lpage>1028</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2018.06.011</pub-id><pub-id pub-id-type="pmid">29902569</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hennebelle</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Metherel</surname><given-names>A. H.</given-names></name><name><surname>Kitson</surname><given-names>A. P.</given-names></name><name><surname>Otoki</surname><given-names>Y.</given-names></name><name><surname>Richardson</surname><given-names>C. E.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Linoleic acid participates in the response to ischemic brain injury through oxidized metabolites that regulate neurotransmission</article-title>. <source/>Sci. Rep.
<volume>7</volume>, <fpage>4342</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-02914-7</pub-id><pub-id pub-id-type="pmid">28659576</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hiratsuka</surname><given-names>S.</given-names></name><name><surname>Koizumi</surname><given-names>K.</given-names></name><name><surname>Ooba</surname><given-names>T.</given-names></name><name><surname>Yokogoshi</surname><given-names>H.</given-names></name></person-group> (<year>2009</year>). <article-title>Effects of dietary docosahexaenoic acid connecting phospholipids on the learning ability and fatty acid composition of the brain</article-title>. <source/>J. Nutr. Sci. Vitaminol. (Tokyo)
<volume>55</volume>, <fpage>374</fpage>–<lpage>380</lpage>. <pub-id pub-id-type="doi">10.3177/jnsv.55.374</pub-id><pub-id pub-id-type="pmid">19763040</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hjorth</surname><given-names>E.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Toro</surname><given-names>V. C.</given-names></name><name><surname>Vedin</surname><given-names>I.</given-names></name><name><surname>Palmblad</surname><given-names>J.</given-names></name><name><surname>Cederholm</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-related amyloid-beta42 by human microglia and decrease inflammatory markers</article-title>. <source/>J. Alzheimers Dis.
<volume>35</volume>, <fpage>697</fpage>–<lpage>713</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-130131</pub-id><pub-id pub-id-type="pmid">23481688</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Gronert</surname><given-names>K.</given-names></name><name><surname>Devchand</surname><given-names>P. R.</given-names></name><name><surname>Moussignac</surname><given-names>R. L.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2003</year>). <article-title>Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>14677</fpage>–<lpage>14687</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M300218200</pub-id><pub-id pub-id-type="pmid">12590139</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hughes</surname><given-names>M. M.</given-names></name><name><surname>Connor</surname><given-names>T. J.</given-names></name><name><surname>Harkin</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Stress-related immune markers in depression: implications for treatment</article-title>. <source/>Int. J. Neuropsychopharmacol.
<fpage>1</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1093/ijnp/pyw001</pub-id><pub-id pub-id-type="pmid">27613293</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Igarashi</surname><given-names>M.</given-names></name><name><surname>Ma</surname><given-names>K.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>Bell</surname><given-names>J. M.</given-names></name><name><surname>Rapoport</surname><given-names>S. I.</given-names></name></person-group> (<year>2007</year>). <article-title>Dietary n-3 PUFA deprivation for 15 weeks upregulates elongase and desaturase expression in rat liver but not brain</article-title>. <source/>J. Lipid Res.
<volume>48</volume>, <fpage>2463</fpage>–<lpage>2470</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M700315-JLR200</pub-id><pub-id pub-id-type="pmid">17715424</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name><name><surname>Masuda</surname><given-names>S.</given-names></name><name><surname>Ohue-Kitano</surname><given-names>R.</given-names></name><name><surname>Yamakage</surname><given-names>H.</given-names></name><name><surname>Muranaka</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Omega-3 polyunsaturated fatty acids suppress the inflammatory responses of lipopolysaccharide-stimulated mouse microglia by activating SIRT1 pathways</article-title>. <source/>Biochim. Biophys. Acta
<volume>1862</volume>, <fpage>552</fpage>–<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2017.02.010</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>Y.</given-names></name><name><surname>Deyama</surname><given-names>S.</given-names></name><name><surname>Shimoda</surname><given-names>K.</given-names></name><name><surname>Yoshikawa</surname><given-names>K.</given-names></name><name><surname>Ide</surname><given-names>S.</given-names></name><name><surname>Satoh</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Rapid and sustained antidepressant effects of resolvin D1 and D2 in a chronic unpredictable stress model</article-title>. <source/>Behav. Brain Res.
<volume>332</volume>, <fpage>233</fpage>–<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2017.06.010</pub-id><pub-id pub-id-type="pmid">28610917</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Isobe</surname><given-names>Y.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Matsueda</surname><given-names>S.</given-names></name><name><surname>Iwamoto</surname><given-names>R.</given-names></name><name><surname>Fujihara</surname><given-names>T.</given-names></name><name><surname>Nakanishi</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>10525</fpage>–<lpage>10534</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.340612</pub-id><pub-id pub-id-type="pmid">22275352</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>James</surname><given-names>S. Y.</given-names></name><name><surname>Williams</surname><given-names>M. A.</given-names></name><name><surname>Kelsey</surname><given-names>S. M.</given-names></name><name><surname>Newland</surname><given-names>A. C.</given-names></name><name><surname>Colston</surname><given-names>K. W.</given-names></name></person-group> (<year>1997</year>). <article-title>The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells</article-title>. <source/>Biochem. Pharmacol.
<volume>54</volume>, <fpage>625</fpage>–<lpage>634</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(97)00195-0</pub-id><pub-id pub-id-type="pmid">9337080</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Joffre</surname><given-names>C.</given-names></name><name><surname>Grégoire</surname><given-names>S.</given-names></name><name><surname>De Smedt</surname><given-names>V.</given-names></name><name><surname>Acar</surname><given-names>N.</given-names></name><name><surname>Bretillon</surname><given-names>L.</given-names></name><name><surname>Nadjar</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Modulation of brain PUFA content in different experimental models of mice</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>114</volume>, <fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2016.09.003</pub-id><pub-id pub-id-type="pmid">27926457</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>J. X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Kang</surname><given-names>Z. B.</given-names></name></person-group> (<year>2004</year>). <article-title>Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids</article-title>. <source/>Nature
<volume>427</volume>, <elocation-id>504</elocation-id>. <pub-id pub-id-type="doi">10.1038/427504a</pub-id><pub-id pub-id-type="pmid">14765186</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kantarci</surname><given-names>A.</given-names></name><name><surname>Aytan</surname><given-names>N.</given-names></name><name><surname>Palaska</surname><given-names>I.</given-names></name><name><surname>Stephens</surname><given-names>D.</given-names></name><name><surname>Crabtree</surname><given-names>L.</given-names></name><name><surname>Benincasa</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer’s disease</article-title>. <source/>Exp. Neurol.
<volume>300</volume>, <fpage>111</fpage>–<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2017.11.005</pub-id><pub-id pub-id-type="pmid">29126887</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kavanagh</surname><given-names>T.</given-names></name><name><surname>Lonergan</surname><given-names>P. E.</given-names></name><name><surname>Lynch</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Eicosapentaenoic acid and gamma-linolenic acid increase hippocampal concentrations of IL-4 and IL-10 and abrogate lipopolysaccharide-induced inhibition of long-term potentiation</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>70</volume>, <fpage>391</fpage>–<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2003.12.014</pub-id><pub-id pub-id-type="pmid">15041032</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kiecolt-Glaser</surname><given-names>J. K.</given-names></name><name><surname>Belury</surname><given-names>M. A.</given-names></name><name><surname>Andridge</surname><given-names>R.</given-names></name><name><surname>Malarkey</surname><given-names>W. B.</given-names></name><name><surname>Hwang</surname><given-names>B. S.</given-names></name><name><surname>Glaser</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial</article-title>. <source/>Brain Behav. Immun.
<volume>26</volume>, <fpage>988</fpage>–<lpage>995</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2012.05.011</pub-id><pub-id pub-id-type="pmid">22640930</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>H. W.</given-names></name><name><surname>Rao</surname><given-names>J. S.</given-names></name><name><surname>Rapoport</surname><given-names>S. I.</given-names></name><name><surname>Igarashi</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Dietary n-6 PUFA deprivation downregulates arachidonate but upregulates docosahexaenoate metabolizing enzymes in rat brain</article-title>. <source/>Biochim. Biophys. Acta
<volume>1811</volume>, <fpage>111</fpage>–<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2010.10.005</pub-id><pub-id pub-id-type="pmid">21070866</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kitson</surname><given-names>A. P.</given-names></name><name><surname>Metherel</surname><given-names>A. H.</given-names></name><name><surname>Chen</surname><given-names>C. T.</given-names></name><name><surname>Domenichiello</surname><given-names>A. F.</given-names></name><name><surname>Trepanier</surname><given-names>M. O.</given-names></name><name><surname>Berger</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Effect of dietary docosahexaenoic acid (DHA) in phospholipids or triglycerides on brain DHA uptake and accretion</article-title>. <source/>J. Nutr. Biochem.
<volume>33</volume>, <fpage>91</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1016/j.jnutbio.2016.02.009</pub-id><pub-id pub-id-type="pmid">27135386</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klein</surname><given-names>C. P.</given-names></name><name><surname>Sperotto</surname><given-names>N. D.</given-names></name><name><surname>Maciel</surname><given-names>I. S.</given-names></name><name><surname>Leite</surname><given-names>C. E.</given-names></name><name><surname>Souza</surname><given-names>A. H.</given-names></name><name><surname>Campos</surname><given-names>M. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice</article-title>. <source/>Neuropharmacology
<volume>86</volume>, <fpage>57</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.05.043</pub-id><pub-id pub-id-type="pmid">24929111</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kremer</surname><given-names>J. M.</given-names></name></person-group> (<year>2000</year>). <article-title>n-3 fatty acid supplements in rheumatoid arthritis</article-title>. <source/>Am. J. Clin. Nutr.
<volume>71</volume>, <fpage>349S</fpage>–<lpage>351S</lpage>. <pub-id pub-id-type="doi">10.1093/ajcn/71.1.349s</pub-id><pub-id pub-id-type="pmid">10617995</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kremer</surname><given-names>J. M.</given-names></name><name><surname>Lawrence</surname><given-names>D. A.</given-names></name><name><surname>Jubiz</surname><given-names>W.</given-names></name><name><surname>DiGiacomo</surname><given-names>R.</given-names></name><name><surname>Rynes</surname><given-names>R.</given-names></name><name><surname>Bartholomew</surname><given-names>L. E.</given-names></name><etal></etal></person-group> (<year>1990</year>). <article-title>Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects</article-title>. <source/>Arthritis Rheum.
<volume>33</volume>, <fpage>810</fpage>–<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1002/art.1780330607</pub-id><pub-id pub-id-type="pmid">2363736</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krishnamoorthy</surname><given-names>S.</given-names></name><name><surname>Recchiuti</surname><given-names>A.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Fredman</surname><given-names>G.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2012</year>). <article-title>Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs</article-title>. <source/>Am. J. Pathol.
<volume>180</volume>, <fpage>2018</fpage>–<lpage>2027</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2012.01.028</pub-id><pub-id pub-id-type="pmid">22449948</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krishnamoorthy</surname><given-names>S.</given-names></name><name><surname>Recchiuti</surname><given-names>A.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Yacoubian</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>C. H.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Resolvin D1 binds human phagocytes with evidence for proresolving receptors</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>107</volume>, <fpage>1660</fpage>–<lpage>1665</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0907342107</pub-id><pub-id pub-id-type="pmid">20080636</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kromann</surname><given-names>N.</given-names></name><name><surname>Green</surname><given-names>A.</given-names></name></person-group> (<year>1980</year>). <article-title>Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974</article-title>. <source/>Acta Med. Scand.
<volume>208</volume>, <fpage>401</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1111/j.0954-6820.1980.tb01221.x</pub-id><pub-id pub-id-type="pmid">7457208</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuda</surname><given-names>O.</given-names></name></person-group> (<year>2017</year>). <article-title>Bioactive metabolites of docosahexaenoic acid</article-title>. <source/>Biochimie
<volume>136</volume>, <fpage>12</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.biochi.2017.01.002</pub-id><pub-id pub-id-type="pmid">28087294</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Labrousse</surname><given-names>V. F.</given-names></name><name><surname>Nadjar</surname><given-names>A.</given-names></name><name><surname>Joffre</surname><given-names>C.</given-names></name><name><surname>Costes</surname><given-names>L.</given-names></name><name><surname>Aubert</surname><given-names>A.</given-names></name><name><surname>Grégoire</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice</article-title>. <source/>PLoS One
<volume>7</volume>, <elocation-id>e36861</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0036861</pub-id><pub-id pub-id-type="pmid">22662127</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lacombe</surname><given-names>R. J. S.</given-names></name><name><surname>Giuliano</surname><given-names>V.</given-names></name><name><surname>Colombo</surname><given-names>S. M.</given-names></name><name><surname>Arts</surname><given-names>M. T.</given-names></name><name><surname>Bazinet</surname><given-names>R. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Compound-specific isotope analysis resolves the dietary origin of docosahexaenoic acid in the mouse brain</article-title>. <source/>J. Lipid Res.
<volume>58</volume>, <fpage>2071</fpage>–<lpage>2081</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.D077990</pub-id><pub-id pub-id-type="pmid">28694298</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lafourcade</surname><given-names>M.</given-names></name><name><surname>Larrieu</surname><given-names>T.</given-names></name><name><surname>Mato</surname><given-names>S.</given-names></name><name><surname>Duffaud</surname><given-names>A.</given-names></name><name><surname>Sepers</surname><given-names>M.</given-names></name><name><surname>Matias</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions</article-title>. <source/>Nat. Neurosci.
<volume>14</volume>, <fpage>345</fpage>–<lpage>350</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2736</pub-id><pub-id pub-id-type="pmid">21278728</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larrieu</surname><given-names>T.</given-names></name><name><surname>Hilal</surname><given-names>M. L.</given-names></name><name><surname>Hilal</surname><given-names>L. M.</given-names></name><name><surname>Fourrier</surname><given-names>C.</given-names></name><name><surname>De Smedt-Peyrusse</surname><given-names>V.</given-names></name><name><surname>Sans</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion</article-title>. <source/>Transl. Psychiatry
<volume>4</volume>, <fpage>e437</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2014.77</pub-id><pub-id pub-id-type="pmid">25203168</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larrieu</surname><given-names>T.</given-names></name><name><surname>Layé</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Food for mood: relevance of nutritional omega-3 fatty acids for depression and anxiety</article-title>. <source/>Front. Physiol.
<volume>9</volume>, <elocation-id>1047</elocation-id>. <pub-id pub-id-type="doi">10.3389/fphys.2018.01047</pub-id><pub-id pub-id-type="pmid">30127751</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larrieu</surname><given-names>T.</given-names></name><name><surname>Madore</surname><given-names>C.</given-names></name><name><surname>Joffre</surname><given-names>C.</given-names></name><name><surname>Layé</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Nutritional n-3 polyunsaturated fatty acids deficiency alters cannabinoid receptor signaling pathway in the brain and associated anxiety-like behavior in mice</article-title>. <source/>J. Physiol. Biochem.
<volume>68</volume>, <fpage>671</fpage>–<lpage>681</lpage>. <pub-id pub-id-type="doi">10.1007/s13105-012-0179-6</pub-id><pub-id pub-id-type="pmid">22707188</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Layé</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Polyunsaturated fatty acids, neuroinflammation and well being</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>82</volume>, <fpage>295</fpage>–<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2010.02.006</pub-id><pub-id pub-id-type="pmid">20227866</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Layé</surname><given-names>S.</given-names></name><name><surname>Nadjar</surname><given-names>A.</given-names></name><name><surname>Joffre</surname><given-names>C.</given-names></name><name><surname>Bazinet</surname><given-names>R. P.</given-names></name></person-group> (<year>2018</year>). <article-title>Anti-inflammatory effects of omega-3 fatty acids in the brain: physiological mechanisms and relevance to pharmacology</article-title>. <source/>Pharmacol. Rev.
<volume>70</volume>, <fpage>12</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1124/pr.117.014092</pub-id><pub-id pub-id-type="pmid">29217656</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lazic</surname><given-names>M.</given-names></name><name><surname>Inzaugarat</surname><given-names>M. E.</given-names></name><name><surname>Povero</surname><given-names>D.</given-names></name><name><surname>Zhao</surname><given-names>I. C.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Nalbandian</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis</article-title>. <source/>PLoS One
<volume>9</volume>, <elocation-id>e107658</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0107658</pub-id><pub-id pub-id-type="pmid">25251155</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>L. K.</given-names></name><name><surname>Shahar</surname><given-names>S.</given-names></name><name><surname>Chin</surname><given-names>A. V.</given-names></name><name><surname>Yusoff</surname><given-names>N. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial</article-title>. <source/>Psychopharmacol. (Berl.)
<volume>225</volume>, <fpage>605</fpage>–<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-012-2848-0</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Levy</surname><given-names>B. D.</given-names></name><name><surname>Clish</surname><given-names>C. B.</given-names></name><name><surname>Schmidt</surname><given-names>B.</given-names></name><name><surname>Gronert</surname><given-names>K.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2001</year>). <article-title>Lipid mediator class switching during acute inflammation: signals in resolution</article-title>. <source/>Nat. Immunol.
<volume>2</volume>, <fpage>612</fpage>–<lpage>619</lpage>. <pub-id pub-id-type="doi">10.1038/89759</pub-id><pub-id pub-id-type="pmid">11429545</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Xian</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Resolvin D1 promotes the interleukin-4-induced alternative activation in BV-2 microglial cells</article-title>. <source/>J. Neuroinflamm.
<volume>11</volume>, <elocation-id>72</elocation-id>. <pub-id pub-id-type="doi">10.1186/1742-2094-11-72</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Little</surname><given-names>S. J.</given-names></name><name><surname>Lynch</surname><given-names>M. A.</given-names></name><name><surname>Manku</surname><given-names>M.</given-names></name><name><surname>Nicolaou</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>Docosahexaenoic acid-induced changes in phospholipids in cortex of young and aged rats: a lipidomic analysis</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>77</volume>, <fpage>155</fpage>–<lpage>162</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2007.08.009</pub-id><pub-id pub-id-type="pmid">17928211</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lonergan</surname><given-names>P. E.</given-names></name><name><surname>Martin</surname><given-names>D. S.</given-names></name><name><surname>Horrobin</surname><given-names>D. F.</given-names></name><name><surname>Lynch</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharide-induced dysfunction in rat hippocampus</article-title>. <source/>J. Neurochem.
<volume>91</volume>, <fpage>20</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02689.x</pub-id><pub-id pub-id-type="pmid">15379883</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>López-Vicario</surname><given-names>C.</given-names></name><name><surname>Rius</surname><given-names>B.</given-names></name><name><surname>Alcaraz-Quiles</surname><given-names>J.</given-names></name><name><surname>García-Alonso</surname><given-names>V.</given-names></name><name><surname>Lopategi</surname><given-names>A.</given-names></name><name><surname>Titos</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases</article-title>. <source/>Eur. J. Pharmacol.
<volume>785</volume>, <fpage>133</fpage>–<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2015.03.092</pub-id><pub-id pub-id-type="pmid">25987424</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>D. Y.</given-names></name><name><surname>Tsao</surname><given-names>Y. Y.</given-names></name><name><surname>Leung</surname><given-names>Y. M.</given-names></name><name><surname>Su</surname><given-names>K. P.</given-names></name></person-group> (<year>2010</year>). <article-title>Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids</article-title>. <source/>Neuropsychopharmacology
<volume>35</volume>, <fpage>2238</fpage>–<lpage>2248</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2010.98</pub-id><pub-id pub-id-type="pmid">20668435</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>L. X.</given-names></name><name><surname>Cao</surname><given-names>D. L.</given-names></name><name><surname>Gao</surname><given-names>Y. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Spinal injection of docosahexaenoic acid attenuates carrageenan-induced inflammatory pain through inhibition of microglia-mediated neuroinflammation in the spinal cord</article-title>. <source/>Neuroscience
<volume>241</volume>, <fpage>22</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.03.003</pub-id><pub-id pub-id-type="pmid">23500096</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lukiw</surname><given-names>W. J.</given-names></name><name><surname>Cui</surname><given-names>J. G.</given-names></name><name><surname>Marcheselli</surname><given-names>V. L.</given-names></name><name><surname>Bodker</surname><given-names>M.</given-names></name><name><surname>Botkjaer</surname><given-names>A.</given-names></name><name><surname>Gotlinger</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease</article-title>. <source/>J. Clin. Invest.
<volume>115</volume>, <fpage>2774</fpage>–<lpage>2783</lpage>. <pub-id pub-id-type="doi">10.1172/JCI25420</pub-id><pub-id pub-id-type="pmid">16151530</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><name><surname>Wan</surname><given-names>J. B.</given-names></name><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Enriched endogenous omega-3 fatty acids in mice protect against global ischemia injury</article-title>. <source/>J. Lipid Res.
<volume>55</volume>, <fpage>1288</fpage>–<lpage>1297</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M046466</pub-id><pub-id pub-id-type="pmid">24875538</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Madore</surname><given-names>C.</given-names></name><name><surname>Leyrolle</surname><given-names>Q.</given-names></name><name><surname>Lacabanne</surname><given-names>C.</given-names></name><name><surname>Benmamar-Badel</surname><given-names>A.</given-names></name><name><surname>Joffre</surname><given-names>C.</given-names></name><name><surname>Nadjar</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Neuroinflammation in autism: plausible role of maternal inflammation, dietary omega 3, and microbiota</article-title>. <source/>Neural. Plast.
<volume>2016</volume>, <elocation-id>3597209</elocation-id>. <pub-id pub-id-type="doi">10.1155/2016/3597209</pub-id><pub-id pub-id-type="pmid">27840741</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Madore</surname><given-names>C.</given-names></name><name><surname>Nadjar</surname><given-names>A.</given-names></name><name><surname>Delpech</surname><given-names>J.-C.</given-names></name><name><surname>Sere</surname><given-names>A.</given-names></name><name><surname>Aubert</surname><given-names>A.</given-names></name><name><surname>Portal</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Nutritional n-3 PUFAs deficiency during perinatal periods alters brain innate immune system and neuronal plasticity-associated genes</article-title>. <source/>Brain Behav. Immun.
<volume>41</volume>, <fpage>22</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2014.03.021</pub-id><pub-id pub-id-type="pmid">24735929</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manduca</surname><given-names>A.</given-names></name><name><surname>Bara</surname><given-names>A.</given-names></name><name><surname>Larrieu</surname><given-names>T.</given-names></name><name><surname>Lassalle</surname><given-names>O.</given-names></name><name><surname>Joffre</surname><given-names>C.</given-names></name><name><surname>Layé</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Amplification of mGlu5-endocannabinoid signaling rescues behavioral and synaptic deficits in a mouse model of adolescent and adult dietary polyunsaturated fatty acid imbalance</article-title>. <source/>J. Neurosci.
<volume>37</volume>, <fpage>6851</fpage>–<lpage>6868</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3516-16.2017</pub-id><pub-id pub-id-type="pmid">28630250</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marcheselli</surname><given-names>V. L.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Lukiw</surname><given-names>W. J.</given-names></name><name><surname>Tian</surname><given-names>X. H.</given-names></name><name><surname>Gronert</surname><given-names>K.</given-names></name><name><surname>Musto</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>43807</fpage>–<lpage>43817</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M305841200</pub-id><pub-id pub-id-type="pmid">12923200</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marcon</surname><given-names>R.</given-names></name><name><surname>Bento</surname><given-names>A. F.</given-names></name><name><surname>Dutra</surname><given-names>R. C.</given-names></name><name><surname>Bicca</surname><given-names>M. A.</given-names></name><name><surname>Leite</surname><given-names>D. F.</given-names></name><name><surname>Calixto</surname><given-names>J. B.</given-names></name></person-group> (<year>2013</year>). <article-title>Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis</article-title>. <source/>J. Immunol.
<volume>191</volume>, <fpage>4288</fpage>–<lpage>4298</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1202743</pub-id><pub-id pub-id-type="pmid">24038091</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mas</surname><given-names>E.</given-names></name><name><surname>Croft</surname><given-names>K. D.</given-names></name><name><surname>Zahra</surname><given-names>P.</given-names></name><name><surname>Barden</surname><given-names>A.</given-names></name><name><surname>Mori</surname><given-names>T. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation</article-title>. <source/>Clin. Chem.
<volume>58</volume>, <fpage>1476</fpage>–<lpage>1484</lpage>. <pub-id pub-id-type="doi">10.1373/clinchem.2012.190199</pub-id><pub-id pub-id-type="pmid">22912397</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McNamara</surname><given-names>R. K.</given-names></name></person-group> (<year>2015</year>). <article-title>Mitigation of inflammation-induced mood dysregulation by long-chain omega-3 fatty acids</article-title>. <source/>J. Am. Coll. Nutr.
<volume>34</volume>
<issue>Suppl 1</issue>, <fpage>48</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1080/07315724.2015.1080527</pub-id><pub-id pub-id-type="pmid">26400435</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McNamara</surname><given-names>R. K.</given-names></name><name><surname>Carlson</surname><given-names>S. E.</given-names></name></person-group> (<year>2006</year>). <article-title>Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>75</volume>, <fpage>329</fpage>–<lpage>349</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2006.07.010</pub-id><pub-id pub-id-type="pmid">16949263</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mingam</surname><given-names>R.</given-names></name><name><surname>Moranis</surname><given-names>A.</given-names></name><name><surname>Bluthé</surname><given-names>R.-M.</given-names></name><name><surname>De Smedt-Peyrusse</surname><given-names>V.</given-names></name><name><surname>Kelley</surname><given-names>K. W.</given-names></name><name><surname>Guesnet</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Uncoupling of interleukin-6 from its signalling pathway by dietary n-3-polyunsaturated fatty acid deprivation alters sickness behaviour in mice</article-title>. <source/>Eur. J. Neurosci.
<volume>28</volume>, <fpage>1877</fpage>–<lpage>1886</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06470.x</pub-id><pub-id pub-id-type="pmid">18973601</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mizwicki</surname><given-names>M. T.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Fiala</surname><given-names>M.</given-names></name><name><surname>Magpantay</surname><given-names>L.</given-names></name><name><surname>Sayre</surname><given-names>J.</given-names></name><name><surname>Siani</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>1alpha,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-beta phagocytosis and inflammation in Alzheimer’s disease patients</article-title>. <source/>J. Alzheimers Dis.
<volume>34</volume>, <fpage>155</fpage>–<lpage>170</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-121735</pub-id><pub-id pub-id-type="pmid">23186989</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moon</surname><given-names>D. O.</given-names></name><name><surname>Kim</surname><given-names>K. C.</given-names></name><name><surname>Jin</surname><given-names>C. Y.</given-names></name><name><surname>Han</surname><given-names>M. H.</given-names></name><name><surname>Park</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>K. J.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Inhibitory effects of eicosapentaenoic acid on lipopolysaccharide-induced activation in BV2 microglia</article-title>. <source/>Int. Immunopharmacol.
<volume>7</volume>, <fpage>222</fpage>–<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2006.10.001</pub-id><pub-id pub-id-type="pmid">17178390</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morgese</surname><given-names>M. G.</given-names></name><name><surname>Schiavone</surname><given-names>S.</given-names></name><name><surname>Mhillaj</surname><given-names>E.</given-names></name><name><surname>Bove</surname><given-names>M.</given-names></name><name><surname>Tucci</surname><given-names>P.</given-names></name><name><surname>Trabace</surname><given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>N-3 PUFA diet enrichment prevents amyloid beta-induced depressive-like phenotype</article-title>. <source/>Pharmacol. Res.
<volume>129</volume>, <fpage>526</fpage>–<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2017.11.034</pub-id><pub-id pub-id-type="pmid">29203442</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mulik</surname><given-names>R. S.</given-names></name><name><surname>Bing</surname><given-names>C.</given-names></name><name><surname>Ladouceur-Wodzak</surname><given-names>M.</given-names></name><name><surname>Munaweera</surname><given-names>I.</given-names></name><name><surname>Chopra</surname><given-names>R.</given-names></name><name><surname>Corbin</surname><given-names>I. R.</given-names></name></person-group> (<year>2016</year>). <article-title>Localized delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat brain using focused ultrasound</article-title>. <source/>Biomaterials
<volume>83</volume>, <fpage>257</fpage>–<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.01.021</pub-id><pub-id pub-id-type="pmid">26790145</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nadjar</surname><given-names>A.</given-names></name><name><surname>Tridon</surname><given-names>V.</given-names></name><name><surname>May</surname><given-names>M. J.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Dantzer</surname><given-names>R.</given-names></name><name><surname>Amedee</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>NFkappaB activates in vivo the synthesis of inducible Cox-2 in the brain</article-title>. <source/>J. Cereb. Blood Flow Metab.
<volume>25</volume>, <fpage>1047</fpage>–<lpage>1059</lpage>. <pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600106</pub-id><pub-id pub-id-type="pmid">15758944</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nassar</surname><given-names>G. M.</given-names></name><name><surname>Morrow</surname><given-names>J. D.</given-names></name><name><surname>Roberts</surname><given-names>L. J.</given-names></name><name><surname>Lakkis</surname><given-names>F. G.</given-names></name><name><surname>Badr</surname><given-names>K. F.</given-names></name></person-group> (<year>1994</year>). <article-title>Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes</article-title>. <source/>J. Biol. Chem.
<volume>269</volume>, <fpage>27631</fpage>–<lpage>27634</lpage>.<pub-id pub-id-type="pmid">7961680</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nebert</surname><given-names>D. W.</given-names></name></person-group> (<year>2017</year>). <article-title>Aryl hydrocarbon receptor (AHR): “pioneer member” of the basic-helix/loop/helix per-Arnt-sim (bHLH/PAS) family of “sensors” of foreign and endogenous signals</article-title>. <source/>Prog. Lipid Res.
<volume>67</volume>, <fpage>38</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.plipres.2017.06.001</pub-id><pub-id pub-id-type="pmid">28606467</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nebert</surname><given-names>D. W.</given-names></name><name><surname>Wikvall</surname><given-names>K.</given-names></name><name><surname>Miller</surname><given-names>W. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Human cytochromes P450 in health and disease</article-title>. <source/>Philos. Trans. R. Soc. Lond. B Biol. Sci.
<volume>368</volume>, <elocation-id>20120431</elocation-id>. <pub-id pub-id-type="doi">10.1098/rstb.2012.0431</pub-id><pub-id pub-id-type="pmid">23297354</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Norling</surname><given-names>L. V.</given-names></name><name><surname>Headland</surname><given-names>S. E.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Arnardottir</surname><given-names>H. H.</given-names></name><name><surname>Haworth</surname><given-names>O.</given-names></name><name><surname>Jones</surname><given-names>H. R.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis</article-title>. <source/>JCI Insight
<volume>1</volume>, <elocation-id>e85922</elocation-id>. <pub-id pub-id-type="doi">10.1172/jci.insight.85922</pub-id><pub-id pub-id-type="pmid">27158677</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oh</surname><given-names>S. F.</given-names></name><name><surname>Pillai</surname><given-names>P. S.</given-names></name><name><surname>Recchiuti</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2011</year>). <article-title>Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation</article-title>. <source/>J. Clin. Invest.
<volume>121</volume>, <fpage>569</fpage>–<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1172/JCI42545</pub-id><pub-id pub-id-type="pmid">21206090</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ohira</surname><given-names>T.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Omori</surname><given-names>K.</given-names></name><name><surname>Recchiuti</surname><given-names>A.</given-names></name><name><surname>Van Dyke</surname><given-names>T. E.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2010</year>). <article-title>Resolvin E1 receptor activation signals phosphorylation and phagocytosis</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>3451</fpage>–<lpage>3461</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.044131</pub-id><pub-id pub-id-type="pmid">19906641</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orr</surname><given-names>S. K.</given-names></name><name><surname>Palumbo</surname><given-names>S.</given-names></name><name><surname>Bosetti</surname><given-names>F.</given-names></name><name><surname>Mount</surname><given-names>H. T.</given-names></name><name><surname>Kang</surname><given-names>J. X.</given-names></name><name><surname>Greenwood</surname><given-names>C. E.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Unesterified docosahexaenoic acid is protective in neuroinflammation</article-title>. <source/>J. Neurochem.
<fpage>378</fpage>–<lpage>393</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.12392</pub-id><pub-id pub-id-type="pmid">23919613</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ostermann</surname><given-names>A. I.</given-names></name><name><surname>Reutzel</surname><given-names>M.</given-names></name><name><surname>Hartung</surname><given-names>N.</given-names></name><name><surname>Franke</surname><given-names>N.</given-names></name><name><surname>Kutzner</surname><given-names>L.</given-names></name><name><surname>Schoenfeld</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>A diet rich in omega-3 fatty acids enhances expression of soluble epoxide hydrolase in murine brain</article-title>. <source/>Prostaglandins Other Lipid Mediat.
<fpage>79</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/j.prostaglandins.2017.06.001</pub-id><pub-id pub-id-type="pmid">28583889</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pallast</surname><given-names>S.</given-names></name><name><surname>Arai</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Lo</surname><given-names>E. H.</given-names></name><name><surname>van Leyen</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>12/15-Lipoxygenase targets neuronal mitochondria under oxidative stress</article-title>. <source/>J. Neurochem.
<volume>111</volume>, <fpage>882</fpage>–<lpage>889</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06379.x</pub-id><pub-id pub-id-type="pmid">19737346</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>C.-K.</given-names></name><name><surname>Xu</surname><given-names>Z.-Z.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Lü</surname><given-names>N.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name><name><surname>Ji</surname><given-names>R.-R.</given-names></name></person-group> (<year>2011</year>). <article-title>Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1</article-title>. <source/>J. Neurosci.
<volume>31</volume>, <fpage>18433</fpage>–<lpage>18438</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4192-11.2011</pub-id><pub-id pub-id-type="pmid">22171045</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pascual</surname><given-names>O.</given-names></name><name><surname>Ben Achour</surname><given-names>S.</given-names></name><name><surname>Rostaing</surname><given-names>P.</given-names></name><name><surname>Triller</surname><given-names>A.</given-names></name><name><surname>Bessis</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>109</volume>, <fpage>E197</fpage>–<lpage>E205</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1111098109</pub-id><pub-id pub-id-type="pmid">22167804</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>La</surname><given-names>M.</given-names></name><name><surname>Fierro</surname><given-names>I. M.</given-names></name><name><surname>Marullo</surname><given-names>S.</given-names></name><name><surname>Getting</surname><given-names>S. J.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor</article-title>. <source/>Nat. Med.
<volume>8</volume>, <fpage>1296</fpage>–<lpage>1302</lpage>. <pub-id pub-id-type="doi">10.1038/nm786</pub-id><pub-id pub-id-type="pmid">12368905</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pettit</surname><given-names>L. K.</given-names></name><name><surname>Varsanyi</surname><given-names>C.</given-names></name><name><surname>Tadros</surname><given-names>J.</given-names></name><name><surname>Vassiliou</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin</article-title>. <source/>Lipids Health Dis.
<volume>12</volume>, <elocation-id>16</elocation-id>. <pub-id pub-id-type="doi">10.1186/1476-511X-12-16</pub-id><pub-id pub-id-type="pmid">23398903</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pietropaolo</surname><given-names>S.</given-names></name><name><surname>Goubran</surname><given-names>M. G.</given-names></name><name><surname>Joffre</surname><given-names>C.</given-names></name><name><surname>Aubert</surname><given-names>A.</given-names></name><name><surname>Lemaire-Mayo</surname><given-names>V.</given-names></name><name><surname>Crusio</surname><given-names>W. E.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Dietary supplementation of omega-3 fatty acids rescues fragile X phenotypes in Fmr1-Ko mice</article-title>. <source/>Psychoneuroendocrinology
<volume>49</volume>, <fpage>119</fpage>–<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2014.07.002</pub-id><pub-id pub-id-type="pmid">25080404</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pratico</surname><given-names>D.</given-names></name><name><surname>Zhukareva</surname><given-names>V.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Uryu</surname><given-names>K.</given-names></name><name><surname>Funk</surname><given-names>C. D.</given-names></name><name><surname>Lawson</surname><given-names>J. A.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>12/15-lipoxygenase is increased in Alzheimer’s disease: possible involvement in brain oxidative stress</article-title>. <source/>Am. J. Pathol.
<volume>164</volume>, <fpage>1655</fpage>–<lpage>1662</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)63724-8</pub-id><pub-id pub-id-type="pmid">15111312</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qu</surname><given-names>L.</given-names></name><name><surname>Caterina</surname><given-names>M. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Accelerating the reversal of inflammatory pain with NPD1 and its receptor GPR37</article-title>. <source/>J. Clin. Invest.
<volume>128</volume>, <fpage>3246</fpage>–<lpage>3249</lpage>. <pub-id pub-id-type="doi">10.1172/JCI122203</pub-id><pub-id pub-id-type="pmid">30010628</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rao</surname><given-names>J. S.</given-names></name><name><surname>Ertley</surname><given-names>R. N.</given-names></name><name><surname>DeMar</surname><given-names>J. C.</given-names><suffix>Jr.</suffix></name><name><surname>Rapoport</surname><given-names>S. I.</given-names></name><name><surname>Bazinet</surname><given-names>R. P.</given-names></name><name><surname>Lee</surname><given-names>H. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex</article-title>. <source/>Mol. Psychiatry
<volume>12</volume>, <fpage>151</fpage>–<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001887</pub-id><pub-id pub-id-type="pmid">16983392</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rapaport</surname><given-names>M. H.</given-names></name><name><surname>Nierenberg</surname><given-names>A. A.</given-names></name><name><surname>Schettler</surname><given-names>P. J.</given-names></name><name><surname>Kinkead</surname><given-names>B.</given-names></name><name><surname>Cardoos</surname><given-names>A.</given-names></name><name><surname>Walker</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study</article-title>. <source/>Mol. Psychiatry
<volume>21</volume>, <fpage>71</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2015.22</pub-id><pub-id pub-id-type="pmid">25802980</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rapoport</surname><given-names>S. I.</given-names></name><name><surname>Rao</surname><given-names>J. S.</given-names></name><name><surname>Igarashi</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>77</volume>, <fpage>251</fpage>–<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2007.10.023</pub-id><pub-id pub-id-type="pmid">18060754</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Recchiuti</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Resolvin D1 and its GPCRs in resolution circuits of inflammation</article-title>. <source/>Prostaglandins Other Lipid Mediat.
<volume>107</volume>, <fpage>64</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.prostaglandins.2013.02.004</pub-id><pub-id pub-id-type="pmid">23500003</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Recchiuti</surname><given-names>A.</given-names></name><name><surname>Krishnamoorthy</surname><given-names>S.</given-names></name><name><surname>Fredman</surname><given-names>G.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2011</year>). <article-title>MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits</article-title>. <source/>Faseb J.
<volume>25</volume>, <fpage>544</fpage>–<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1096/fj.10-169599</pub-id><pub-id pub-id-type="pmid">20956612</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Renaud</surname><given-names>J.</given-names></name><name><surname>Therien</surname><given-names>H. M.</given-names></name><name><surname>Plouffe</surname><given-names>M.</given-names></name><name><surname>Martinoli</surname><given-names>M. G.</given-names></name></person-group> (<year>2015</year>). <article-title>[Neuroinflammation: Dr Jekyll or Mr Hyde?]</article-title>. <source/>Med. Sci. (Paris)
<volume>31</volume>, <fpage>979</fpage>–<lpage>988</lpage>. <pub-id pub-id-type="doi">10.1051/medsci/20153111012</pub-id><pub-id pub-id-type="pmid">26576605</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rey</surname><given-names>C.</given-names></name><name><surname>Delpech</surname><given-names>J. C.</given-names></name><name><surname>Madore</surname><given-names>C.</given-names></name><name><surname>Nadjar</surname><given-names>A.</given-names></name><name><surname>Greenhalgh</surname><given-names>A. D.</given-names></name><name><surname>Amadieu</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Dietary n-3 long chain PUFA supplementation promotes a pro-resolving oxylipin profile in the brain</article-title>. <source/>Brain Behav. Immun.
<volume>76</volume>, <fpage>17</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2018.07.025</pub-id><pub-id pub-id-type="pmid">30086401</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rey</surname><given-names>C.</given-names></name><name><surname>Nadjar</surname><given-names>A.</given-names></name><name><surname>Buaud</surname><given-names>B.</given-names></name><name><surname>Vaysse</surname><given-names>C.</given-names></name><name><surname>Aubert</surname><given-names>A.</given-names></name><name><surname>Pallet</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Resolvin D1 and E1 promote resolution of inflammation in microglial cells in vitro</article-title>. <source/>Brain Behav. Immun.
<volume>55</volume>, <fpage>249</fpage>–<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.12.013</pub-id><pub-id pub-id-type="pmid">26718448</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rey</surname><given-names>C.</given-names></name><name><surname>Nadjar</surname><given-names>A.</given-names></name><name><surname>Joffre</surname><given-names>F.</given-names></name><name><surname>Amadieu</surname><given-names>C.</given-names></name><name><surname>Aubert</surname><given-names>A.</given-names></name><name><surname>Vaysse</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Maternal n-3 polyunsaturated fatty acid dietary supply modulates microglia lipid content in the offspring</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>133</volume>, <fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2018.04.003</pub-id><pub-id pub-id-type="pmid">29789127</pub-id></mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosenberger</surname><given-names>T. A.</given-names></name><name><surname>Villacreses</surname><given-names>N. E.</given-names></name><name><surname>Hovda</surname><given-names>J. T.</given-names></name><name><surname>Bosetti</surname><given-names>F.</given-names></name><name><surname>Weerasinghe</surname><given-names>G.</given-names></name><name><surname>Wine</surname><given-names>R. N.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide</article-title>. <source/>J. Neurochem.
<volume>88</volume>, <fpage>1168</fpage>–<lpage>1178</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.02246.x</pub-id><pub-id pub-id-type="pmid">15009672</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>M. D.</given-names></name><name><surname>Patel</surname><given-names>J.</given-names></name><name><surname>Staton</surname><given-names>K.</given-names></name><name><surname>Martindale</surname><given-names>R. G.</given-names></name><name><surname>Moore</surname><given-names>F. A.</given-names></name><name><surname>Upchurch</surname><given-names>G. R.</given-names></name></person-group> (<year>2018</year>). <article-title>Can specialized pro-resolving mediators deliver benefit originally expected from fish oil</article-title>? <source/>Curr. Gastroenterol. Rep.
<volume>20</volume>, <fpage>40</fpage>. <pub-id pub-id-type="doi">10.1007/s11894-018-0647-4</pub-id><pub-id pub-id-type="pmid">30078085</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rossi</surname><given-names>S.</given-names></name><name><surname>Di Filippo</surname><given-names>C.</given-names></name><name><surname>Gesualdo</surname><given-names>C.</given-names></name><name><surname>Potenza</surname><given-names>N.</given-names></name><name><surname>Russo</surname><given-names>A.</given-names></name><name><surname>Trotta</surname><given-names>M. C.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Protection from endotoxic uveitis by intravitreal Resolvin D1: involvement of lymphocytes, miRNAs, ubiquitin-proteasome, and M1/M2 macrophages</article-title>. <source/>Mediators Inflamm.
<volume>2015</volume>, <elocation-id>149381</elocation-id>. <pub-id pub-id-type="doi">10.1155/2015/149381</pub-id><pub-id pub-id-type="pmid">25684860</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salinas</surname><given-names>G.</given-names></name><name><surname>Rangasetty</surname><given-names>U. C.</given-names></name><name><surname>Uretsky</surname><given-names>B. F.</given-names></name><name><surname>Birnbaum</surname><given-names>Y.</given-names></name></person-group> (<year>2007</year>). <article-title>The cycloxygenase 2 (COX-2) story: it’s time to explain, not inflame</article-title>. <source/>J. Cardiovasc. Pharmacol. Ther.
<volume>12</volume>, <fpage>98</fpage>–<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1177/1074248407301172</pub-id><pub-id pub-id-type="pmid">17562780</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwab</surname><given-names>J. M.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2007</year>). <article-title>Resolvin E1 and protectin D1 activate inflammation-resolution programmes</article-title>. <source/>Nature
<volume>447</volume>, <fpage>869</fpage>–<lpage>874</lpage>. <pub-id pub-id-type="doi">10.1038/nature05877</pub-id><pub-id pub-id-type="pmid">17568749</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2014</year>). <article-title>Pro-resolving lipid mediators are leads for resolution physiology</article-title>. <source/>Nature
<volume>510</volume>, <fpage>92</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1038/nature13479</pub-id><pub-id pub-id-type="pmid">24899309</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2017</year>a). <article-title>Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology</article-title>. <source/>Mol. Aspects Med.
<volume>58</volume>, <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2017.03.001</pub-id><pub-id pub-id-type="pmid">28263773</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2017</year>b). <article-title>Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms</article-title>. <source/>FASEB J.
<volume>31</volume>, <fpage>1273</fpage>–<lpage>1288</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201601222R</pub-id><pub-id pub-id-type="pmid">28087575</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name></person-group> (<year>2013</year>). <article-title>Resolution phase lipid mediators of inflammation: agonists of resolution</article-title>. <source/>Curr. Opin. Pharmacol.
<volume>13</volume>, <fpage>632</fpage>–<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2013.05.012</pub-id><pub-id pub-id-type="pmid">23747022</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution</article-title>. <source/>Semin. Immunol.
<volume>27</volume>, <fpage>200</fpage>–<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1016/j.smim.2015.03.004</pub-id><pub-id pub-id-type="pmid">25857211</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration</article-title>. <source/>Mol. Aspects Med.
<volume>64</volume>, <fpage>1</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2017.08.002</pub-id><pub-id pub-id-type="pmid">28802833</pub-id></mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name><name><surname>Clish</surname><given-names>C. B.</given-names></name><name><surname>Brannon</surname><given-names>J.</given-names></name><name><surname>Colgan</surname><given-names>S. P.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Gronert</surname><given-names>K.</given-names></name></person-group> (<year>2000</year>). <article-title>Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing</article-title>. <source/>J. Exp. Med.
<volume>192</volume>, <fpage>1197</fpage>–<lpage>1204</lpage>. <pub-id pub-id-type="doi">10.1084/jem.192.8.1197</pub-id><pub-id pub-id-type="pmid">11034610</pub-id></mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Gronert</surname><given-names>K.</given-names></name><name><surname>Colgan</surname><given-names>S. P.</given-names></name><name><surname>Devchand</surname><given-names>P. R.</given-names></name><name><surname>Mirick</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals</article-title>. <source/>J. Exp. Med.
<volume>196</volume>, <fpage>1025</fpage>–<lpage>1037</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20020760</pub-id><pub-id pub-id-type="pmid">12391014</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name><name><surname>Petasis</surname><given-names>N. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Resolvins and protectins in inflammation resolution</article-title>. <source/>Chem. Rev.
<volume>111</volume>, <fpage>5922</fpage>–<lpage>5943</lpage>. <pub-id pub-id-type="doi">10.1021/cr100396c</pub-id><pub-id pub-id-type="pmid">21766791</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name><name><surname>Savill</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>Resolution of inflammation: the beginning programs the end</article-title>. <source/>Nat. Immunol.
<volume>6</volume>, <fpage>1191</fpage>–<lpage>1197</lpage>. <pub-id pub-id-type="doi">10.1038/ni1276</pub-id><pub-id pub-id-type="pmid">16369558</pub-id></mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Martinod</surname><given-names>K.</given-names></name><name><surname>Kasuga</surname><given-names>K.</given-names></name><name><surname>Pillai</surname><given-names>P. S.</given-names></name><name><surname>Porter</surname><given-names>T. F.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions</article-title>. <source/>J. Exp. Med.
<volume>206</volume>, <fpage>15</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20081880</pub-id><pub-id pub-id-type="pmid">19103881</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shalini</surname><given-names>S. M.</given-names></name><name><surname>Ho</surname><given-names>C. F.</given-names></name><name><surname>Ng</surname><given-names>Y. K.</given-names></name><name><surname>Tong</surname><given-names>J. X.</given-names></name><name><surname>Ong</surname><given-names>E. S.</given-names></name><name><surname>Herr</surname><given-names>D. R.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Distribution of Alox15 in the rat brain and its role in prefrontal cortical resolvin D1 formation and spatial working memory</article-title>. <source/>Mol. Neurobiol.
<fpage>1537</fpage>–<lpage>1550</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-017-0413-x</pub-id><pub-id pub-id-type="pmid">28181190</pub-id></mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sheets</surname><given-names>K. G.</given-names></name><name><surname>Jun</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Petasis</surname><given-names>N. A.</given-names></name><name><surname>Gordon</surname><given-names>W. C.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Microglial ramification and redistribution concomitant with the attenuation of choroidal neovascularization by neuroprotectin D1</article-title>. <source/>Mol. Vis.
<volume>19</volume>, <fpage>1747</fpage>–<lpage>1759</lpage>.<pub-id pub-id-type="pmid">23922492</pub-id></mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shevalye</surname><given-names>H.</given-names></name><name><surname>Yorek</surname><given-names>M. S.</given-names></name><name><surname>Coppey</surname><given-names>L. J.</given-names></name><name><surname>Holmes</surname><given-names>A.</given-names></name><name><surname>Harper</surname><given-names>M. M.</given-names></name><name><surname>Kardon</surname><given-names>R. H.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes</article-title>. <source/>J. Neurophysiol.
<volume>114</volume>, <fpage>199</fpage>–<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00224.2015</pub-id><pub-id pub-id-type="pmid">25925322</pub-id></mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>B.</given-names></name><name><surname>Yao</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Fish oil prevents lipopolysaccharide-induced depressive-like behavior by inhibiting neuroinflammation</article-title>. <source/>Mol. Neurobiol.
<fpage>7327</fpage>–<lpage>7334</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-0212-9</pub-id><pub-id pub-id-type="pmid">27815837</pub-id></mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siegert</surname><given-names>E.</given-names></name><name><surname>Paul</surname><given-names>F.</given-names></name><name><surname>Rothe</surname><given-names>M.</given-names></name><name><surname>Weylandt</surname><given-names>K. H.</given-names></name></person-group> (<year>2017</year>). <article-title>The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice</article-title>. <source/>BMC Neurosci.
<volume>18</volume>, <fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/s12868-016-0312-5</pub-id><pub-id pub-id-type="pmid">28114887</pub-id></mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simopoulos</surname><given-names>A. P.</given-names></name></person-group> (<year>2008</year>). <article-title>The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases</article-title>. <source/>Exp. Biol. Med. (Maywood)
<volume>233</volume>, <fpage>674</fpage>–<lpage>688</lpage>. <pub-id pub-id-type="doi">10.3181/0711-MR-311</pub-id><pub-id pub-id-type="pmid">18408140</pub-id></mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skarke</surname><given-names>C.</given-names></name><name><surname>Alamuddin</surname><given-names>N.</given-names></name><name><surname>Lawson</surname><given-names>J. A.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ferguson</surname><given-names>J. F.</given-names></name><name><surname>Reilly</surname><given-names>M. P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Bioactive products formed in humans from fish oils</article-title>. <source/>J. Lipid Res.
<volume>56</volume>, <fpage>1808</fpage>–<lpage>1820</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M060392</pub-id><pub-id pub-id-type="pmid">26180051</pub-id></mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skorve</surname><given-names>J.</given-names></name><name><surname>Hilvo</surname><given-names>M.</given-names></name><name><surname>Vihervaara</surname><given-names>T.</given-names></name><name><surname>Burri</surname><given-names>L.</given-names></name><name><surname>Bohov</surname><given-names>P.</given-names></name><name><surname>Tillander</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Fish oil and krill oil differentially modify the liver and brain lipidome when fed to mice</article-title>. <source/>Lipids Health Dis.
<volume>14</volume>, <fpage>88</fpage>. <pub-id pub-id-type="doi">10.1186/s12944-015-0086-2</pub-id><pub-id pub-id-type="pmid">26260413</pub-id></mixed-citation>
</ref>
<ref id="B199">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Solito</surname><given-names>E.</given-names></name><name><surname>Sastre</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Microglia function in Alzheimer’s disease</article-title>. <source/>Front. Pharmacol.
<volume>3</volume>, <elocation-id>14</elocation-id>. <pub-id pub-id-type="doi">10.3389/fphar.2012.00014</pub-id><pub-id pub-id-type="pmid">22363284</pub-id></mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Horrobin</surname><given-names>D.</given-names></name></person-group> (<year>2004</year>). <article-title>Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1beta administration</article-title>. <source/>J. Lipid Res.
<volume>45</volume>, <fpage>1112</fpage>–<lpage>1121</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M300526-JLR200</pub-id><pub-id pub-id-type="pmid">15060086</pub-id></mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Manku</surname><given-names>M. S.</given-names></name><name><surname>Horrobin</surname><given-names>D. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Long-chain polyunsaturated fatty acids modulate interleukin-1beta-induced changes in behavior, monoaminergic neurotransmitters, and brain inflammation in rats</article-title>. <source/>J. Nutr.
<volume>138</volume>, <fpage>954</fpage>–<lpage>963</lpage>. <pub-id pub-id-type="doi">10.1093/jn/138.5.954</pub-id><pub-id pub-id-type="pmid">18424607</pub-id></mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spanbroek</surname><given-names>R.</given-names></name><name><surname>Hildner</surname><given-names>M.</given-names></name><name><surname>Kohler</surname><given-names>A.</given-names></name><name><surname>Muller</surname><given-names>A.</given-names></name><name><surname>Zintl</surname><given-names>F.</given-names></name><name><surname>Kuhn</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>98</volume>, <fpage>5152</fpage>–<lpage>5157</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.091076998</pub-id><pub-id pub-id-type="pmid">11320251</pub-id></mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spite</surname><given-names>M.</given-names></name><name><surname>Norling</surname><given-names>L. V.</given-names></name><name><surname>Summers</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Cooper</surname><given-names>D.</given-names></name><name><surname>Petasis</surname><given-names>N. A.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis</article-title>. <source/>Nature
<volume>461</volume>, <fpage>1287</fpage>–<lpage>1291</lpage>. <pub-id pub-id-type="doi">10.1038/nature08541</pub-id><pub-id pub-id-type="pmid">19865173</pub-id></mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spite</surname><given-names>M.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2010</year>). <article-title>Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins</article-title>. <source/>Circ. Res.
<volume>107</volume>, <fpage>1170</fpage>–<lpage>1184</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.223883</pub-id><pub-id pub-id-type="pmid">21071715</pub-id></mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stewart</surname><given-names>T. M.</given-names></name><name><surname>Bowling</surname><given-names>A. C.</given-names></name></person-group> (<year>2005</year>). <article-title>Polyunsaturated fatty acid supplementation in MS</article-title>. <source/>Int. MS. J.
<volume>12</volume>, <fpage>88</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">16417822</pub-id></mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>M. A.</given-names></name><name><surname>Sousa</surname><given-names>L. P.</given-names></name><name><surname>Pinho</surname><given-names>V.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Teixeira</surname><given-names>M. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Resolution of inflammation: what controls its onset</article-title>? <source/>Front. Immunol.
<volume>7</volume>, <elocation-id>160</elocation-id>. <pub-id pub-id-type="doi">10.3389/fimmu.2016.00160</pub-id><pub-id pub-id-type="pmid">27199985</pub-id></mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>Y. W.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>12/15-Lipoxygenase metabolites of arachidonic acid activate PPARgamma: a possible neuroprotective effect in ischemic brain</article-title>. <source/>J. Lipid Res.
<volume>56</volume>, <fpage>502</fpage>–<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M053058</pub-id><pub-id pub-id-type="pmid">25605873</pub-id></mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Z. P.</given-names></name><name><surname>Gui</surname><given-names>P.</given-names></name><name><surname>Xia</surname><given-names>W.</given-names></name><name><surname>Xia</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>X. C.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Endogenous expression pattern of resolvin D1 in a rat model of self-resolution of lipopolysaccharide-induced acute respiratory distress syndrome and inflammation</article-title>. <source/>Int. Immunopharmacol.
<volume>23</volume>, <fpage>247</fpage>–<lpage>253</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2014.09.001</pub-id><pub-id pub-id-type="pmid">25218162</pub-id></mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y. P.</given-names></name><name><surname>Oh</surname><given-names>S. F.</given-names></name><name><surname>Uddin</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Gotlinger</surname><given-names>K.</given-names></name><name><surname>Campbell</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation</article-title>. <source/>J. Biol. Chem.
<volume>282</volume>, <fpage>9323</fpage>–<lpage>9334</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M609212200</pub-id><pub-id pub-id-type="pmid">17244615</pub-id></mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taha</surname><given-names>A. Y.</given-names></name><name><surname>Blanchard</surname><given-names>H. C.</given-names></name><name><surname>Cheon</surname><given-names>Y.</given-names></name><name><surname>Ramadan</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Dietary linoleic acid lowering reduces lipopolysaccharide-induced increase in brain arachidonic acid metabolism</article-title>. <source/>Mol. Neurobiol.
<volume>54</volume>, <fpage>4303</fpage>–<lpage>4315</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-9968-1</pub-id><pub-id pub-id-type="pmid">27339880</pub-id></mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taha</surname><given-names>A. Y.</given-names></name><name><surname>Hennebelle</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zamora</surname><given-names>D.</given-names></name><name><surname>Rapoport</surname><given-names>S. I.</given-names></name><name><surname>Hammock</surname><given-names>B. D.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids.
<pub-id pub-id-type="doi">10.1016/j.plefa.2016.05.004</pub-id></mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terrando</surname><given-names>N.</given-names></name><name><surname>Gomez-Galan</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>T.</given-names></name><name><surname>Carlstrom</surname><given-names>M.</given-names></name><name><surname>Gustavsson</surname><given-names>D.</given-names></name><name><surname>Harding</surname><given-names>R. E.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline</article-title>. <source/>FASEB J.
<volume>27</volume>, <fpage>3564</fpage>–<lpage>3571</lpage>. <pub-id pub-id-type="doi">10.1096/fj.13-230276</pub-id><pub-id pub-id-type="pmid">23709617</pub-id></mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomazeau</surname><given-names>A.</given-names></name><name><surname>Bosch-Bouju</surname><given-names>C.</given-names></name><name><surname>Manzoni</surname><given-names>O.</given-names></name><name><surname>Layé</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Nutritional n-3 PUFA deficiency abolishes endocannabinoid gating of hippocampal long-term potentiation</article-title>. <source/>Cereb. Cortex
<volume>27</volume>, <fpage>2571</fpage>–<lpage>2579</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhw052</pub-id><pub-id pub-id-type="pmid">26946127</pub-id></mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Qiao</surname><given-names>S.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Resolvin D2 recovers neural injury by suppressing inflammatory mediators expression in lipopolysaccharide-induced Parkinson’s disease rat model</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>460</volume>, <fpage>799</fpage>–<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2015.03.109</pub-id><pub-id pub-id-type="pmid">25824039</pub-id></mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Titos</surname><given-names>E.</given-names></name><name><surname>Rius</surname><given-names>B.</given-names></name><name><surname>Gonzalez-Periz</surname><given-names>A.</given-names></name><name><surname>Lopez-Vicario</surname><given-names>C.</given-names></name><name><surname>Moran-Salvador</surname><given-names>E.</given-names></name><name><surname>Martinez-Clemente</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype</article-title>. <source/>J. Immunol.
<volume>187</volume>, <fpage>5408</fpage>–<lpage>5418</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1100225</pub-id><pub-id pub-id-type="pmid">22013115</pub-id></mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>M. E.</given-names></name><name><surname>Zhang</surname><given-names>I.</given-names></name><name><surname>Bisht</surname><given-names>K.</given-names></name><name><surname>Savage</surname><given-names>J. C.</given-names></name><name><surname>Lecours</surname><given-names>C.</given-names></name><name><surname>Parent</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Remodeling of lipid bodies by docosahexaenoic acid in activated microglial cells</article-title>. <source/>J. Neuroinflamm.
<volume>13</volume>, <fpage>116</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-016-0580-0</pub-id></mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trépanier</surname><given-names>M.-O.</given-names></name><name><surname>Hopperton</surname><given-names>K. E.</given-names></name><name><surname>Giuliano</surname><given-names>V.</given-names></name><name><surname>Masoodi</surname><given-names>M.</given-names></name><name><surname>Bazinet</surname><given-names>R. P.</given-names></name></person-group> (<year>2018</year>). <article-title>Increased brain docosahexaenoic acid has no effect on the resolution of neuroinflammation following intracerebroventricular lipopolysaccharide injection</article-title>. <source/>Neurochem. Int.
<volume>118</volume>, <fpage>115</fpage>–<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2018.05.010</pub-id><pub-id pub-id-type="pmid">29792954</pub-id></mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Key role of 15-LO/15-HETE in angiogenesis and functional recovery in later stages of post-stroke mice</article-title>. <source/>Sci. Rep.
<volume>7</volume>, <elocation-id>46698</elocation-id>. <pub-id pub-id-type="doi">10.1038/srep46698</pub-id><pub-id pub-id-type="pmid">28436420</pub-id></mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>R. X.</given-names></name><name><surname>Colgan</surname><given-names>S. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Special pro-resolving mediator (SPM) actions in regulating gastro-intestinal inflammation and gut mucosal immune responses</article-title>. <source/>Mol. Aspects Med.
<volume>58</volume>, <fpage>93</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2017.02.002</pub-id><pub-id pub-id-type="pmid">28232096</pub-id></mixed-citation>
</ref>
<ref id="B220">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Hjorth</surname><given-names>E.</given-names></name><name><surname>Cortes-Toro</surname><given-names>V.</given-names></name><name><surname>Eyjolfsdottir</surname><given-names>H.</given-names></name><name><surname>Graff</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Resolution of inflammation is altered in Alzheimer’s disease</article-title>. <source/>Alzheimers Dement.
<volume>11</volume>, 40-50 <fpage>e1</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2013.12.024</pub-id><pub-id pub-id-type="pmid">26073027</pub-id></mixed-citation>
</ref>
<ref id="B221">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Botolin</surname><given-names>D.</given-names></name><name><surname>Christian</surname><given-names>B.</given-names></name><name><surname>Busik</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Jump</surname><given-names>D. B.</given-names></name></person-group> (<year>2005</year>). <article-title>Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases</article-title>. <source/>J. Lipid Res.
<volume>46</volume>, <fpage>706</fpage>–<lpage>715</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M400335-JLR200</pub-id><pub-id pub-id-type="pmid">15654130</pub-id></mixed-citation>
</ref>
<ref id="B222">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y. P.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>L. Y.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>R. G.</given-names></name><name><surname>Zhou</surname><given-names>J. P.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Aspirin-triggered lipoxin A4 attenuates LPS-induced pro-inflammatory responses by inhibiting activation of NF-kappaB and MAPKs in BV-2 microglial cells</article-title>. <source/>J. Neuroinflamm.
<volume>8</volume>, <elocation-id>95</elocation-id>. <pub-id pub-id-type="doi">10.1186/1742-2094-8-95</pub-id></mixed-citation>
</ref>
<ref id="B223">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weinstock-Guttman</surname><given-names>B.</given-names></name><name><surname>Baier</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>Y.</given-names></name><name><surname>Feichter</surname><given-names>J.</given-names></name><name><surname>Lee-Kwen</surname><given-names>P.</given-names></name><name><surname>Gallagher</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>73</volume>, <fpage>397</fpage>–<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2005.05.024</pub-id><pub-id pub-id-type="pmid">16099630</pub-id></mixed-citation>
</ref>
<ref id="B224">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiser</surname><given-names>M. J.</given-names></name><name><surname>Mucha</surname><given-names>B.</given-names></name><name><surname>Denheyer</surname><given-names>H.</given-names></name><name><surname>Atkinson</surname><given-names>D.</given-names></name><name><surname>Schanz</surname><given-names>N.</given-names></name><name><surname>Vassiliou</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Dietary docosahexaenoic acid alleviates autistic-like behaviors resulting from maternal immune activation in mice</article-title>. <source/>Prostaglandins Leukot. Essent. Fatty Acids
<volume>106</volume>, <fpage>27</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2015.10.005</pub-id><pub-id pub-id-type="pmid">26703213</pub-id></mixed-citation>
</ref>
<ref id="B225">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Winkler</surname><given-names>J. W.</given-names></name><name><surname>Orr</surname><given-names>S. K.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>C. Y.</given-names></name><name><surname>Sanger</surname><given-names>J. M.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Resolvin D4 stereoassignment and its novel actions in host protection and bacterial clearance</article-title>. <source/>Sci. Rep.
<volume>6</volume>, <elocation-id>18972</elocation-id>. <pub-id pub-id-type="doi">10.1038/srep18972</pub-id><pub-id pub-id-type="pmid">26743932</pub-id></mixed-citation>
</ref>
<ref id="B226">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xian</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Maresin 1 attenuates the inflammatory response and mitochondrial damage in mice with cerebral ischemia/reperfusion in a SIRT1-dependent manner</article-title>. <source/>Brain Res.
<fpage>83</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2019.01.013</pub-id></mixed-citation>
</ref>
<ref id="B227">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xian</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Xiong</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Pan</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>The pro-resolving lipid mediator Maresin 1 protects against cerebral ischemia/reperfusion injury by attenuating the pro-inflammatory response</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>472</volume>, <fpage>175</fpage>–<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.02.090</pub-id><pub-id pub-id-type="pmid">26915798</pub-id></mixed-citation>
</ref>
<ref id="B228">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Z. Y.</given-names></name></person-group> (<year>2005</year>). <article-title>Distribution, depletion and recovery of docosahexaenoic acid are region-specific in rat brain</article-title>. <source/>Br. J. Nutr.
<volume>94</volume>, <fpage>544</fpage>–<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1079/BJN20051539</pub-id><pub-id pub-id-type="pmid">16197579</pub-id></mixed-citation>
</ref>
<ref id="B229">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z. Z.</given-names></name><name><surname>Berta</surname><given-names>T.</given-names></name><name><surname>Ji</surname><given-names>R. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>8</volume>, <fpage>37</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-012-9394-8</pub-id><pub-id pub-id-type="pmid">22878925</pub-id></mixed-citation>
</ref>
<ref id="B230">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z. Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Park</surname><given-names>J. Y.</given-names></name><name><surname>Berta</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions</article-title>. <source/>Nat. Med.
<volume>16</volume>, <page-range>592–7</page-range>, 1p following 597. <pub-id pub-id-type="doi">10.1038/nm.2123</pub-id></mixed-citation>
</ref>
<ref id="B231">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yao</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name></person-group> (<year>2013</year>). <article-title>Neuroprotectin D1 attenuates brain damage induced by transient middle cerebral artery occlusion in rats through TRPC6/CREB pathways</article-title>. <source/>Mol. Med. Rep.
<volume>8</volume>, <fpage>543</fpage>–<lpage>550</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2013.1543</pub-id><pub-id pub-id-type="pmid">23799606</pub-id></mixed-citation>
</ref>
<ref id="B232">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yigitkanli</surname><given-names>K.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Pekcec</surname><given-names>A.</given-names></name><name><surname>Lo</surname><given-names>E. H.</given-names></name><name><surname>van Leyen</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>Increased 12/15-lipoxygenase leads to widespread brain injury following global cerebral ischemia</article-title>. <source/>Transl. Stroke Res.
<volume>8</volume>, <fpage>194</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1007/s12975-016-0509-z</pub-id><pub-id pub-id-type="pmid">27838820</pub-id></mixed-citation>
</ref>
<ref id="B233">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yirmiya</surname><given-names>R.</given-names></name><name><surname>Goshen</surname><given-names>I.</given-names></name></person-group> (<year>2011</year>). <article-title>Immune modulation of learning, memory, neural plasticity and neurogenesis</article-title>. <source/>Brain Behav. Immun.
<volume>25</volume>, <fpage>181</fpage>–<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2010.10.015</pub-id><pub-id pub-id-type="pmid">20970492</pub-id></mixed-citation>
</ref>
<ref id="B234">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Hjorth</surname><given-names>E.</given-names></name><name><surname>Colas</surname><given-names>R. A.</given-names></name><name><surname>Schroeder</surname><given-names>L.</given-names></name><name><surname>Granholm</surname><given-names>A. C.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Pro-resolving lipid mediators improve neuronal survival and increase abeta42 phagocytosis</article-title>. <source/>Mol. Neurobiol.
<volume>53</volume>, <fpage>2733</fpage>–<lpage>2749</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-015-9544-0</pub-id><pub-id pub-id-type="pmid">26650044</pub-id></mixed-citation>
</ref>
<ref id="B235">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zimmer</surname><given-names>L.</given-names></name><name><surname>Delpal</surname><given-names>S.</given-names></name><name><surname>Guilloteau</surname><given-names>D.</given-names></name><name><surname>Aioun</surname><given-names>J.</given-names></name><name><surname>Durand</surname><given-names>G.</given-names></name><name><surname>Chalon</surname><given-names>S.</given-names></name></person-group> (<year>2000</year>). <article-title>Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex</article-title>. <source/>Neurosci. Lett.
<volume>284</volume>, <fpage>25</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3940(00)00950-2</pub-id><pub-id pub-id-type="pmid">10771153</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>